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Background: Novel cardioprotective strategies are required to improve clinical outcomes in higher-risk
patients undergoing coronary artery bypass graft (CABG) with or without valve surgery. Remote ischaemic
preconditioning (RIPC) in which brief episodes of non-lethal ischaemia and reperfusion are applied to the
arm or leg has been demonstrated to reduce perioperative myocardial injury (PMI) following CABG with or
without valve surgery.
Objective: To investigate whether or not RIPC can improve clinical outcomes in this setting in the Effect of
Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing Coronary Artery bypass
graft surgery (ERICCA) study in patients undergoing CABG surgery.
Design: Multicentre, double-blind, randomised sham controlled trial.
Setting: The study was conducted across 30 cardiothoracic centres in the UK between March 2010 and
March 2015.
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Participants: Eligible patients were higher-risk adult patients (aged > 18 years of age; additive European
System for Cardiac Operative Risk of ≥ 5) undergoing on-pump CABG with or without valve surgery with
blood cardioplegia.
Interventions: Patients were randomised to receive either RIPC (four 5-minute inflations/deflations of a
standard blood pressure cuff placed on the upper arm) or the sham control procedure (simulated RIPC
protocol) following anaesthetic induction and prior to surgical incision. Anaesthetic management and
perioperative care were not standardised.
Main outcome measures: The combined primary end point was the rate of major adverse cardiac and
cerebral events comprising cardiovascular death, myocardial infarction, coronary revascularisation and
stroke within 12 months of randomisation. Secondary end points included perioperative myocardial and
acute kidney injury (AKI), intensive care unit and hospital stay, inotrope score, left ventricular ejection
fraction, changes in quality of life and exercise tolerance.
Results: In total, 1612 patients (sham control group, n= 811; RIPC group, n= 801) were randomised in
30 cardiac surgery centres in the UK. There was no difference in the primary end point at 12 months
between the RIPC group and the sham control group (26.5% vs. 27.7%; hazard ratio 0.95,
95% confidence interval 0.79 to 1.15; p= 0.58). Furthermore, there was no evidence for any differences
in either adverse events or the secondary end points of PMI (72-hour area under the curve for serum
high-sensitivity troponin T), inotrope score, AKI, intensive therapy unit and hospital stay, 6-minute walk
test and quality of life.
Conclusions: In patients undergoing elective on-pump CABG with or without valve surgery, without
standardisation of the anaesthetic regimen, RIPC using transient arm ischaemia–reperfusion did not
improve clinical outcomes. It is important that studies continue to investigate the potential mechanisms
underlying RIPC, as this may facilitate the translation of this simple, non-invasive, low-cost intervention into
patient benefit. The limitations of the study include the lack of standardised pre-/perioperative anaesthesia
and medication, the level of missing and incomplete data for some of the secondary end points and the
incompleteness of the data for the echocardiography substudy.
Trial registration: ClinicalTrials.gov NCT01247545.
Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a MRC and
NIHR partnership, and the British Heart Foundation.
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Plain English summary
Coronary heart disease (CHD) is the leading cause of death in the UK, accounting for 124,000 deaths in2006 and costing the UK economy over £7.9B per year. Patients with severe CHD are usually treated
by an operation called coronary artery bypass graft (CABG) surgery. This operation can carry risks,
particularly in sicker patients. New treatment strategies are therefore required to improve the outcome and
recovery of these higher-risk patients undergoing CABG surgery.
The ERICCA (Effect of Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing
Coronary Artery bypass graft surgery) trial investigated a new method for reducing the damage to the
heart muscle during CABG surgery with or without valve surgery. The intervention assessed was remote
ischaemic preconditioning (RIPC), which is a low-cost, non-invasive strategy. RIPC consists of placing a
blood pressure cuff on the upper arm to temporarily reduce blood flow to the arm. Smaller studies have
indicated that reducing the blood flow to the arm for a short period of time can protect internal organs
from injury caused by interruption of blood supply, which occurs during major operations such as CABG
surgery. The temporary cessation of blood flow to the arm activates a reflex that makes internal organs
more resistant to the harmful effects of low blood flow. This reflex is called RIPC.
A total of 1612 patients were recruited from 30 hospitals in the UK. All patients were allocated to receive
either RIPC or a ‘pretend’ procedure (control group). The cuff was inflated continuously on the arm for a
5-minute period and was then deflated for 5 minutes. This was performed four times. The cuff was
applied after anaesthetic and before surgery started.
Patients were followed up after 1 year, when information was collected on the primary end point,
consisting of a combination of the rate of death, myocardial infarction, stroke and requirement for
repeat revascularisation.
We found no difference in the primary end point between patients who received the RIPC intervention and
those receiving the intervention simulating RIPC, thereby demonstrating that RIPC provides no additional
benefit to patients undergoing CABG surgery with or without valve surgery.
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Scientific summary
Background
Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the world. Coronary artery
bypass graft (CABG) surgery is the revascularisation strategy of choice, particularly in patients with complex
CAD or diabetes and/or when aged > 65 years. More recently, higher-risk patients are being operated on
because of the ageing population, the more complex CAD being operated on, coexistent comorbidities
(including diabetes and hypertension) and the increasing occurrence of combined valve surgery. All of these
factors together increase perioperative risk, with a significantly higher incidence of death, stroke and acute
kidney injury (AKI) therefore seen in these patients. Another important implication of the increasing risk
profile of subjects undergoing CABG surgery is the higher magnitude of perioperative myocardial injury
(PMI), which has been recognised as being potentially attributable to a number of pathogenetic factors,
the most important of which is ischaemia–reperfusion injury. Ischaemia–reperfusion injury is sustained as a
consequence of intermittent aortic cross-clamping, intermittent or continuous administration of cardioplegia,
or cross-clamp fibrillation. This can be measured using imaging diagnostic modalities and most importantly
with the postoperative rise in serum concentrations of cardiac biomarkers, such as creatine kinase MB and
troponin T or I. Studies have demonstrated that a postoperative increase in such cardiac biomarkers is
associated with worse short- and long-term clinical outcomes, with increases in morbidity and mortality.
Therefore, novel cardioprotective strategies are required to protect these patients to reduce PMI and the
incidence of potentially devastating complications including stroke, AKI and death.
In this regard, remote ischaemic preconditioning (RIPC), which describes the phenomenon by which brief
episodes of transient ischaemia–reperfusion of an organ or tissue distant from another organ or tissue are
able to protect the latter from ischaemia–reperfusion, has emerged as a novel, non-invasive and low-cost
intervention capable of reducing PMI in patients undergoing cardiac surgery and therefore improving
short- and long-term clinical outcomes in these subjects. Since its description in an animal model by
Przyklenk et al. in 1993 and its first application in healthy human volunteers by Kharbanda et al. in 2002,
the concept of RIPC has been applied to different clinical settings including elective cardiac surgery,
non-cardiac surgery, elective or primary percutaneous coronary intervention and organ transplantation
(Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic ‘preconditioning’ protects
remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893–9;
Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, et al. Transient limb
ischemia induces remote ischemic preconditioning in vivo. Circulation 2002;106:2881–3). However,
particularly in the context of elective CABG surgery, outcomes from randomised clinical trials have been
often discordant and this could be for a number of reasons, including patient characteristics, the clinical
setting and the use of concomitant medications. Crucially, the vast majority of these studies were relatively
small proof-of-concept trials primarily investigating the potential effects of RIPC on PMI and only a much
smaller proportion of studies assessed RIPC implications for clinical outcomes, a finding for which such
studies were not sufficiently powered.
We therefore conducted a multicentre randomised sham controlled trial to investigate the effects of RIPC
on clinical outcomes in higher-risk patients undergoing CABG surgery with or without valve surgery [the
Effect of Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing Coronary Artery
bypass graft surgery (ERICCA) trial].
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Objectives
The specific research questions addressed in this trial were:
l Does RIPC improve the combined primary end point of death, revascularisation, stroke and myocardial
infarction (MI) in higher-risk patients undergoing CABG surgery with or without valve surgery at
12 months post surgery?
l Does RIPC improve any of these clinical outcomes individually in higher-risk patients undergoing CABG
surgery with or without valve surgery at 30 days and 12 months post surgery?
l Does RIPC improve PMI, AKI, inotrope requirement, intensive care and hospital stay duration and
quality of life in higher-risk patients undergoing CABG surgery with or without valve surgery?
Methods
The ERICCA trial recruited 1612 higher-risk [euroSCORE (European System for Cardiac Operative Risk) of
≥ 5] patients undergoing CABG with or without valve surgery from 30 surgical centres in the UK.
Patients randomised to receive RIPC had a standard blood pressure cuff placed on the upper arm and
inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle that was performed four
times in total. The control group received simulated 5-minute inflations/deflations of a standard blood
pressure cuff placed on the upper arm, a cycle that was repeated four times. These interventions were
undertaken after the induction of anaesthesia.
The primary analysis compared the rate of major adverse cardiac and cerebrovascular events (MACCE)
within 12 months between the RIPC arm and the sham control arm using Cox proportional hazards models.
The same time-to-event methods were used to evaluate 30-day MACCE; components of 30-day and
12-month MACCE; and all-cause death at 12 months. To compare subgroups with regard to the effect of
treatment on the incidence of MACCE, we included an interaction between treatment group and the
subgroup variable in the time-to-event model. The primary analysis was conducted on an intention-to-treat
(ITT) basis and included all participants regardless of whether the RIPC or sham control procedure was
performed and whether or not CABG (with or without valve) surgery was performed. We also carried out a
per-protocol (PP) analysis that was restricted to participants who received the RIPC and sham control
protocols as specified and underwent CABG (with or without valve) surgery.
Results
Between April 2011 and March 2014, 1612 patients undergoing on-pump CABG (with or without valve)
surgery with blood cardioplegia were recruited. The treatment groups (n= 811 sham control group,
n= 801 in RIPC group) were well balanced in respect of both patient baseline characteristics and surgical
details. Use of cardiovascular medications during follow-up was similar in the two treatment groups. There
were very few participants lost to follow-up before 12 months [28 (3%) sham control group vs. 19 (2%)
RIPC group]. All 1612 patients were included in the analysis of the primary outcome.
The proportion of participants with the MACCE primary end point within 12 months was similar between
the groups [26.5% (n= 212) RIPC group vs. 27.7% (n= 225) control group; hazard ratio (HR) 0.95, 95%
confidence interval (CI) 0.79 to 1.15; p= 0.58]. We found no difference between the groups in any of the
individual components of MACCE (cardiovascular death, MI, stroke and coronary revascularisation).
The results of the PP analysis and ITT analyses were very similar, with little difference in the incidence of
MACCE between the intervention groups. In the PP analysis 27.2% (n= 188/691) of participants in the
RIPC group experienced MACCE within 12 months compared with 28.5% (n= 204/717) in the sham
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control group (HR 0.95, 95% CI 0.78 to 1.16; p= 0.64). No evidence was identified that the effect of RIPC
was different between any of the prespecified subgroups, including age, euroSCORE, cross-clamp and
bypass times, left ventricular ejection function and diabetes.
In addition, multiple imputation analyses undertaken to account for missing data on the perioperative
high-sensitivity troponin T (hsTnT) assay provided no evidence of a reduction in total hsTnT release in the
3 postoperative days (observed 2.0% reduction, 95% CI 9% reduction to 6% increase; p= 0.63).
Participants in the RIPC arm had a walk distance on the 6-minute walk test (6MWT) at 12 months that was
23.3 metres further than that of sham control participants (95% CI 2.2 to 44.4 metres); however, only
785 participants completed the 6MWT on one or more occasions and this finding should therefore be
interpreted cautiously.
There was no evidence of any effect of RIPC on any of the other secondary end points, including the rate
of the combined end point at 30 days, death within 12 months, postoperative atrial fibrillation, AKI,
postoperative release of neutrophil gelatinase-associated lipocalin (a marker of renal injury) and duration
of intensive care unit and hospital stay.
There was no difference in the rate of adverse events between the RIPC group and the control group, with
364 out of 801 cases (45.4%) compared with 354 out of 811 cases (43.6%) respectively. Understandably,
35 out of 736 patients in the RIPC group (4.8%) compared with 2 out of 760 patients in the sham group
(0.3%) experienced skin petechiae at the time of the intervention, albeit with no long-term consequences.
A similar proportion in the RIPC and sham control groups experienced adverse events at times other than
during the RIPC/sham control intervention [n= 318/811 (39%) vs. n= 314/801 (39%)]: however, none of
these events was considered to be related to the intervention.
Conclusions
Remote ischaemic preconditioning, consisting of four 5-minute cycles of ischaemia–reperfusion of the
upper arm, did not improve clinical outcomes in higher-risk patients undergoing elective on-pump CABG
with or without valve surgery.
It is possible that RIPC might provide beneficial effects in different clinical settings. In the context of ST
segment elevation MI patients treated with primary percutaneous coronary intervention, the magnitude of
PMI is substantially greater than for cardiac surgery; in this regard, the CONDI2 (Effect of RIC on Clinical
Outcomes in STEMI Patients Undergoing pPCI)/ERIC-PPCI (Effect of Remote Ischaemic Conditioning on
Clinical Outcomes in STEMI Patients Undergoing PPCI) trial [see www.clinicaltrials.gov: NCT01857414 and
NCT02342522 (accessed 17 March 2016)] will investigate the effect of RIPC on major clinical outcomes in
this group of patients. In addition, the recently completed REPAIR (REmote preconditioning for Protection
Against Ischaemia–Reperfusion in renal transplantation) trial (ISRCTN30083294) found that RIPC using
transient arm ischaemia–reperfusion preserved renal graft function at 12 months following renal
transplantation. It is therefore crucial to continue to investigate the potential mechanisms underlying RIPC
as this may facilitate the translation of this simple, non-invasive, risk-free, low-cost intervention into
beneficial effects on patient outcomes.
Trial registration
This trial is registered as ClinicalTrials.gov NCT01247545.
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Chapter 1 Introduction
Background
Coronary heart disease (CHD) is the leading cause of death in the UK and accounted for 155,000 deaths
in 2014 [see www.heartstats.org (accessed 5 May 2016)]. It is estimated to cost the UK economy over
£7.9B per year, of which 45% is attributed to direct health-care costs (the cost of hospital care and drugs),
40% is attributed to productivity losses (as a result of CHD mortality and morbidity) and 15% is attributed
to the informal care of such patients [see www.heartstats.org (accessed 5 May 2016)]. Therefore,
improving health outcomes in patients with CHD is a major priority of the NHS, as outlined in the National
Service Framework for Coronary Heart Disease1 and embodied in several clinical guidelines and technology
appraisals issued by the National Institute for Health and Care Excellence.2
Coronary artery bypass graft (CABG) surgery remains the procedure of choice for coronary artery
revascularisation in a large number of CHD patients, particularly in patients with triple vessel coronary
artery disease (CAD), as highlighted in the recently published SYNergy between percutaneous coronary
intervention with TAXus and cardiac surgery (SYNTAX) study, which demonstrated improved clinical
outcomes with CABG surgery compared with percutaneous coronary intervention (PCI) in this patient
group.3 About 20,000 first-time CABG operations are performed in the UK each year, with an overall
operative mortality risk of about 1.0% for elective CABG surgery.4 Innovative treatment strategies are
required to reduce myocardial injury and improve clinical outcomes in patients undergoing CABG surgery
and, in this regard, one potential approach is remote ischaemic preconditioning (RIPC).
Remote ischaemic preconditioning
Remote ischaemic preconditioning describes the phenomenon in which the application of brief episodes of
non-lethal ischaemia and reperfusion to an organ (such as the kidney, liver or small intestine) or tissue
(such as skeletal muscle) protects the heart against a sustained episode of lethal ischaemia–reperfusion
injury.5,6 The discovery that the RIPC stimulus could be reproduced by applying brief episodes of ischaemia
and reperfusion to the upper or lower limb7,8 has facilitated its recent translation from animal studies into
the clinical arena.
MacAllister et al.9–11 first demonstrated the concept of RIPC in human volunteers using a non-invasive RIPC
stimulus that involved inflating a blood pressure cuff applied to the upper arm to 200mmHg for 5 minutes
(to induce brief ischaemia) and deflating the cuff for 5 minutes (to induce brief reperfusion), a cycle that
was repeated two more times.9 This RIPC stimulus attenuated ischaemia-induced endothelial dysfunction in
the contralateral arm arising from a 20-minute episode of sustained cuff inflation.9 Cheung et al.12 were
the first to apply this RIPC protocol in the clinical arena in a study in which four 5-minute cycles of lower-
limb ischaemia and reperfusion reduced myocardial injury, improved airway resistance and decreased
inotrope score in children undergoing cardiac surgery. We have demonstrated that three 5-minute cycles
of upper-limb ischaemia and reperfusion had the potential to reduce myocardial injury (43% reduction in
serum troponin T released over 72 hours) in adult patients undergoing elective CABG with or without valve
surgery.13,14 This last proof-of-concept clinical study forms the pilot data for the current study.
Remote ischaemic preconditioning using lower-limb ischaemia and reperfusion has also been reported to
be beneficial in terms of cardiac, renal and neurological protection in the setting of elective surgery for
abdominal aortic aneurysm (AAA)15,16 and surgery for cervical decompression.17 Ali et al.16 demonstrated
that invasive lower-limb ischaemia using two 10-minute episodes of iliac artery occlusion reduced
myocardial injury (as indicated by a 27% reduction in serum troponin I) and preserved renal function
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during elective AAA surgical repair. Hoole et al.18 have reported that RIPC using brief ischaemia and
reperfusion of the arm reduced the periprocedural myocardial injury associated with elective PCI for stable
CAD. Finally, Bøtker et al.19 have demonstrated that RIPC using four 5-minute cuff inflations/deflations
administered in the ambulance reduced myocardial infarct (MI) size in ST elevation myocardial infarction
(STEMI) patients undergoing primary PCI. In the current research protocol, we used this particular RIPC
protocol consisting of four 5-minute cycles of cuff inflation and deflation.
Therefore, although several proof-of-concept studies have been published, whether or not RIPC can impact
on clinical outcomes and improve patient health care in higher-risk patients undergoing CABG with or
without valve surgery is unknown and was the subject of the current research study.
Rationale for the study
The risk profile of patients undergoing CABG surgery continues to change with factors such as (1) the
ageing population (the proportion of patients aged > 75 years increased by more than 4.5-fold from 1990
to 1999, with the 5-year mortality rate in this age group being 35%) and (2) the increasing prevalence of
diabetes (the proportion of diabetic patients has risen from 15% to 22%, with the operative mortality in
this patient group being 2.6%), resulting in an increase in the number of higher-risk patients [we have
defined ‘high risk’ as an additive euroSCORE (European System for Cardiac Operative Risk) of ≥ 5] being
operated on and a corresponding increase in the overall operative risk to 5–6%.20 It has been estimated
that at least 50% of patients undergoing CABG surgery in our recruiting centres have an additive
euroSCORE of ≥ 5.
These higher-risk patients are at a greater risk of sustaining periprocedural myocardial injury, requiring
inotropic support post surgery, experiencing significant acute kidney injury (AKI) (up to 34% of patients)21
and experiencing a stroke (1–3%),22 resulting in worse clinical outcomes. Clearly, new treatment strategies
are required to protect the heart, the brain and the kidney during higher-risk CABG with or without valve
surgery, such that clinical outcomes can be improved in this patient group. This research study investigated
a non-invasive, virtually cost-free intervention called RIPC that has the potential to improve clinical
outcomes in CHD patients undergoing higher-risk CABG with or without valve surgery.
Perioperative myocardial injury (PMI), as measured by serum creatine kinase MB (CKMB),23 troponin T24–26
or troponin I27–29 during surgery, has been associated with worse clinical outcomes post surgery. Therefore,
treatment interventions capable of reducing PMI in the setting of CABG with or without valve surgery may
preserve left ventricular systolic function and improve clinical outcomes. The incidence of AKI following
cardiac surgery can be as high as 30%, with up to 2% of patients going on to require dialysis.30–32 Even
after adjustment for patient comorbidities and surgical complications of the surgical procedure, the
presence of AKI requiring dialysis increases the risk of death by 7.9 times compared with those patients
not developing AKI.33 Furthermore, it has been reported that changes in creatinine of > 0.5mg/dl
(44mmol/l) after cardiac surgery also contribute to a significant increase in mortality at 30 days
post surgery.34
Remote ischaemic preconditioning prior to elective surgical repair of an AAA was reported to preserve
renal function post surgery.15,16 Whether or not RIPC is able to preserve renal function in the setting of
CABG with or without valve surgery remains to be determined.
As previously described, RIPC using three 5-minute cycles of arm ischaemia and reperfusion was associated
with a 43% reduction in total troponin T release in patients undergoing elective CABG with or without
valve surgery at the University College London Hospitals (UCLH) Heart Hospital.13 We have gone on to
demonstrate that the beneficial effect of RIPC extends to CABG with or without valve surgery patients
receiving cold-blood cardioplegia alone.14
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A similar RIPC stimulus can reduce myocardial injury in children undergoing cardiac surgery for congenital
heart disease,12 reduce myocardial and renal injury in patients undergoing surgical repair of an AAA,15,16
reduce neurological injury during cervical decompression surgery17 and reduce myocardial injury in stable
CHD patients undergoing elective PCI18 or STEMI patients undergoing primary PCI.19,35–38
However, all of these clinical trials are proof-of-concept studies and whether or not RIPC can improve
clinical outcomes is unclear. In this study we have investigated whether or not in a large multicentre
randomised controlled clinical trial, RIPC using brief upper-limb ischaemia and reperfusion can impact on
short-term and long-term clinical outcomes in higher-risk patients undergoing CABG with or without
valve surgery.
Trial objectives
The single main research question in terms of PICO (population, intervention, comparator, outcome) was
as follows: ‘In higher-risk adult patients undergoing CABG with or without valve surgery, does RIPC
induced by brief arm ischaemia and reperfusion improve clinical outcomes at 1 year compared with a
control protocol?’
Primary research objective
The primary research objective was to determine whether or not RIPC improves 1-year clinical outcomes in
patients undergoing CABG with or without valve surgery.
Secondary research objectives
1. To determine if RIPC improves 30-day clinical outcomes in patients undergoing CABG with or without
valve surgery.
2. To determine if RIPC has an effect on all-cause death at 12 months.
3. To determine if RIPC reduces PMI in higher-risk patients undergoing CABG with or without valve
surgery (assessed by measuring serum troponin T over the 72-hour perioperative period).
4. To determine if RIPC reduces AKI and preserves renal function post CABG with or without valve surgery
[assessed by measuring serum neutrophil gelatinase-associated lipocalin (NGAL) and serum creatinine
and the AKI score].
5. To determine if RIPC improves patient morbidity as measured by duration of intensive therapy unit (ITU)
stay, inotrope score, the 6-minute walk test (6MWT) and quality-of-life assessment.
6. In a substudy of patients recruited through selected hospitals to determine the effect of RIPC on left
ventricular ejection fraction (LVEF) measured by echocardiography.
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Chapter 2 Methods
Study design
This study was a multicentre, double-blind, randomised controlled trial (RCT) assessing the effect of RIPC
on major adverse cardiac and cerebral events (MACCE) consisting of cardiovascular death, MI, coronary
revascularisation and stroke 12 months following CABG with or without valve surgery, in 30 cardiac
surgery centres in the UK. Patients were randomised in a 1 : 1 ratio to receive either RIPC or a sham
protocol, which was carried out immediately prior to surgery while patients were anaesthetised.
Aim
The Effect of Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing Coronary
Artery bypass graft surgery (ERICCA) trial investigated whether or not RIPC improves long-term clinical
outcomes after cardiac surgery. RIPC is a simple, non-invasive and virtually cost-free intervention and any
reduction in MACCE would indicate an improved outcome following CABG. The findings will also have
implications for the use of RIPC in other clinical ischaemic syndromes.
Participants
The trial intended to recruit 1610 higher-risk patients undergoing CABG from centres in the UK.
Higher-risk patients undergoing CABG with or without valve surgery were invited to take part in the trial.
The final inclusion and exclusion criteria were as follows:
l inclusion criteria
¢ patients undergoing CABG with or without valve surgery
¢ patients aged ≥ 18 years
¢ additive euroSCORE of ≥ 5
l exclusion criteria
¢ cardiogenic shock (the definition used for this was systolic blood pressure of < 90mmHg for
30 minutes before inotrope/vasopressor administration or vasopressors or intra-aortic balloon pump
are required to maintain systolic blood pressure of > 90mmHg)
¢ cardiac arrest on current admission
¢ pregnancy
¢ significant peripheral arterial disease affecting the upper limb
¢ significant hepatic dysfunction (international normalised ratio of > 2)
¢ significant pulmonary disease (forced expiratory volume in 1 second of < 40% predicted)
¢ known renal failure with a glomerular filtration rate of < 30ml/minute/1.73 m2
¢ taking glibenclamide or nicorandil as these medications may interfere with RIPC
¢ recruited into another study that may impact on the ERICCA study.
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There were major protocol amendments that affected the inclusion and exclusion criteria. These were:
l Peripheral vascular disease was changed to peripheral arterial disease as the former was felt to be
vague and includes venous disease such as deep-vein thrombosis. Peripheral arterial disease was felt to
be more accurate and specific to the type of patients to be included.
l A positive troponin T or I at baseline was removed from the exclusion criteria. This was because such a
result was not always known as this was not routinely measured at baseline.
l The euroSCORE was lowered from ≥ 6 to ≥ 5 to aid with the recruitment of patients.
l Patients with a bilirubin level of > 20mmol/l were originally excluded but this was removed as an
exclusion criterion to enhance recruitment.
A full list of protocol amendments can be found in Appendix 1.
Recruitment
The 30 centres included in the study were the Royal Brompton Hospital, London; Harefield Hospital,
Middlesex; UCLH Heart Hospital, London; King’s College Hospital, London; Papworth Hospital, Cambridge;
Hammersmith Hospital, London; St George’s Hospital, London; St Thomas’ Hospital, London; London
Chest Hospital; Essex Cardiothoracic Centre, Basildon; Royal Sussex County Hospital, Brighton; Royal
Wolverhampton Hospitals NHS Trust; Bristol Royal Infirmary; Golden Jubilee National Hospital, Clydebank;
Edinburgh Royal Infirmary; Morriston Hospital, Swansea; Cardiff and Vale University Health Board;
Manchester Royal Infirmary; Derriford Hospital, Plymouth; Northern General Hospital, Sheffield; Trent
Cardiac Centre, Nottingham; Blackpool Victoria Hospital; Wythenshawe Hospital, Manchester; Glenfield
Hospital, Leicester; Southampton General Hospital; Leeds General Infirmary; James Cook University
Hospital, Middlesbrough; North Staffordshire University Hospital, Stoke-on-Trent; Castle Hill Hospital, Hull;
and University Hospital Coventry.
Patients were recruited from two groups: outpatients on the waiting list for CABG surgery or inpatients
awaiting CABG surgery.
Randomisation, concealment and blinding
Patients were randomly assigned in a 1 : 1 ratio to receive sham RIPC or RIPC with randomly permuted
block sizes of four and six stratified by recruiting centre. Randomisation was conducted via a secure
website (Sealed Envelope™; Clekenwell Workshops, London, UK) through the Clinical Trials Unit (CTU) at
the London School of Hygiene & Tropical Medicine (LSHTM).
The enrolment and preconditioning procedures were performed by an unblinded research nurse or
clinician who was not involved in sample or data collection. Cardiac anaesthetists, cardiac surgeons,
ITU staff, ward staff and all other research personnel at each study site were blinded to the treatment
allocation. The patients were also blinded to the allocation of their randomised intervention as they were
anaesthetised at the time of the RIPC intervention. A limited number of staff at the CTU were unblinded to
the allocations to enable them to enter data onto the electronic case report form (eCRF), which was a
web-based data capture system provided by Sealed Envelope. The unblinded trial statistician supporting
the Data Monitoring Committee (DMC) also had access to the randomisation codes during the study.
However, no member of staff at the CTU who was involved in the collection of outcome data had access
to the treatment allocation of the patients.
Interventions
The trial intervention was a physiological procedure and was performed on patients after induction of
anaesthesia but prior to CABG surgery. There were no other interventions. The active RIPC procedure
consisted of four 5-minute inflations of a standard blood pressure cuff on the upper arm to 200mmHg
separated by 5-minute periods when the cuff was deflated. For patients with systolic blood pressure of
> 185mmHg the cuff was inflated to at least 15mmHg above their systolic blood pressure. The sham RIPC
procedure, which also used a standard blood pressure cuff, consisted of four 5-minute simulated inflations
METHODS
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of the blood pressure cuff on the upper arm. The simulated inflations involved opening the air valve on the
blood pressure cuff such that the cuff did not inflate on squeezing the bulb. The bulb was then squeezed
for a duration of 15 seconds to give the impression that the cuff was being inflated. After 5 minutes the
air valve was closed again to give the impression that the cuff was being deflated. After 5 minutes the air
valve was opened again and the bulb squeezed as before. This cycle was undertaken four times in total.
Data collection and management
Randomisation and collection of data on completion of the interventions were performed by the unblinded
research staff. The intervention data were then faxed to the CTU where the data were entered onto the
eCRF and then stored in locked cabinets. Paper copies were requested to ensure that the forms were
signed by the person carrying out the intervention or sham procedure. Following this, all subsequent
follow-up visits and data collection were completed by blinded research staff at the hospitals. A paper case
report form (CRF) was provided to assist with data collection but the source data were considered to be
those in the eCRF. A series of logic and range checks were built into the system to reduce the possibility of
erroneous data being entered. The system also contained a log that detailed all notable events associated
with the trial (including inserts, updates and deletions) and this provided a clear and complete audit trail
throughout the trial. The data management processes were conducted following the principles of Good
Clinical Practice39 and the Data Protection Act 1998.40
Monitoring and site visits
The first site visit was a pre-recruitment visit for training (demonstration of the trial intervention and
procedures) and to ensure that all relevant documentation was in place prior to recruitment commencing.
After the first patient was recruited in each site, the senior data manager provided training on the eCRF.
This training either took place as part of a visit to the site or was performed remotely using the standard
operating procedure document.
On-site monitoring visits were not conducted routinely as this was a low-risk trial; they took place only if
problems were identified (e.g. poor data collection or under-reporting of primary end point data) or when
a site requested a visit to discuss specific issues (including data collection, screening patients, recruitment
and staff training).
After the first five patients had been recruited and completed the 6-week follow-up, the CTU reviewed
data from each site. If no problems were identified the sites were informed that there was no need for a
site monitoring visit. Data validation was then conducted centrally by statistical monitoring across all sites.
If problems were identified, the CTU would contact the relevant site to discuss the situation and arrange a
site monitoring visit.
Central statistical monitoring was performed by the unblinded statistician by reviewing event rates, unusual
trends and data anomalies.
Baseline assessment
At baseline all patients had a medical history taken and a clinical examination as part of usual care.
Baseline information collected included weight, height, sex, ethnicity, blood pressure, heart rate,
electrocardiogram (ECG), date of birth, euroSCORE, medication, levels of creatinine, troponin T, NGAL and
biomarkers, 6MWT distance and European Quality of Life-5 Dimensions (EQ-5D) questionnaire; patients
were also given a patient diary to record health resource use and an echocardiogram was obtained if they
were part of the substudy.
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Follow-up
All patients were followed up approximately 6 weeks post CABG. They were reviewed in clinic as per
normal standard of care. Investigations performed at this visit were the 6MWT, creatinine level, ECG and
EQ-5D questionnaire; the patient diary was also checked for health resource use.
At 3, 6 and 9 months post CABG all patients were requested to complete an EQ-5D questionnaire, which
was carried out by post, telephone or e-mail.
At 1 year post CABG all patients were reviewed, when possible, in a research outpatient clinic. If they were
unable to attend in person the follow-up was completed by telephone. General practitioner and hospital
notes were checked for any events. At this visit, when possible, the following information was collected:
weight, heart rate, blood pressure, recording of primary end points, ECG, creatinine level, echocardiogram
(if part of the substudy), 6MWT distance and EQ-5D questionnaire; the patient diary was also checked for
resource use.
Safety assessments
All untoward occurrences were termed adverse events rather than adverse reactions. Adverse events were
assessed for relatedness to the intervention and were reported to the sponsor and the DMC. Safety
assessments were collected from the time of randomisation to the completion of follow-up. There was a
list of expected adverse events (both serious and non-serious) for which information was not collected.
A detailed listing of individual adverse events was supplied as part of the reports to the DMC.
Outcome measures
Primary outcome
The primary study end point was the rate of MACCE consisting of cardiovascular death, MI, coronary
revascularisation and stroke within 12 months of surgery.
Prespecified secondary outcomes were:
1. 30-day MACCE
2. components of 30-day and 12-month MACCE
3. 12-month MACCE including definite MIs and strokes only
4. death from all causes
5. 72-hour area under the curve (AUC) troponin T
6. AKI injury score after 72 hours
7. serum creatinine level at baseline, 6 weeks and 12 months
8. 24-hour AUC NGAL
9. length of ITU stay
10. inotrope score after 72 hours
11. length of hospital stay
12. 6MWT at 6 weeks and 12 months
13. quality of life (EQ-5D) at 6 weeks and 3, 6, 9 and 12 months
14. substudy: ejection fraction at 12 months.
An additional secondary outcome was postoperative atrial fibrillation (AF), which was selected for analysis
after finalising the statistical analysis plan and unblinding the trial data.
METHODS
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Collection of outcome data
Cardiovascular death included death resulting from an acute MI, sudden cardiac death, death from heart
failure, death from stroke and death from other cardiovascular causes. This also included those deaths in
which there was no clear non-cardiovascular cause. MI included perioperative MI (occurring within
72 hours of surgery) and postoperative MI (occurring >72 hours following surgery). Perioperative MI was
defined as (1) troponin T level > 10 times the 99th percentile of the normal reference range (≥ 14 ng/ml)
during the first 72 hours following surgery associated with the appearance of new pathological Q waves or
new left bundle branch block or angiographically documented new graft or native coronary artery
occlusion or imaging evidence of new loss of viable myocardium or (2) a troponin T level > 100 times the
99th percentile of the normal reference range during the first 72 hours following surgery (≥ 140 ng/ml) or
(3) ECG evidence of perioperative MI in the absence of postsurgery troponin T results. Postoperative MI
was defined as a MI occurring > 72 hours following the operation (definition of MI according to
recent guidelines41).
Repeat coronary revascularisation was defined as repeat PCI or CABG of any segment of the coronary
arteries. Stroke was defined as a focal neurological deficit of cerebrovascular cause that persisted beyond
24 hours or was interrupted by death within 24 hours.
Collection of major adverse cardiac and cerebrovascular events
Data were collected on the eCRF in relation to any events. An initial evaluation was made by the principal
investigator (PI), or someone delegated by the PI, at each of the recruiting centres.
An independent Event Validation Committee (EVC) was set up consisting of a cardiologist (chairperson),
surgeon and neurologist. All members were blinded to treatment allocation. Every effort was made to
collect as much information as possible for assessing the events. A LSHTM-hosted secure file-sharing
system was used to load the event data. Access to this was password protected and could be accessed at
a time that suited each of the committee members. Quarterly conference calls were arranged to discuss
adjudication of events and agree a final classification. In cases in which a unanimous decision could not be
made the majority classification was used.
The following was used to classify each category.
Death
All members of the EVC reviewed descriptions of the circumstances surrounding the death, the certified
cause of death (if available) and autopsy information (if available). The primary cause of death was
classified using one of the following:
l cardiovascular death
l non-cardiovascular death
l unknown.
Myocardial infarction
All ECGs submitted were reviewed for the presence of new Q waves and left bundle branch block.
Troponin T or I results and CKMB level were all reviewed when available. The MI was then classified using
one of the following:
l perioperative MI
l definite MI, which included the following categories: STEMI and MIs that are not definitive STEMI
l probable MI
l no evidence of MI.
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Stroke
All members of the EVC reviewed data on clinical features, an assessment from the hospital where the
event occurred, written reports of computerised tomography scans [if any doubt the imaging was
requested on compact disc (CD)] and any other relevant information.
The stroke was then classified into one of the following:
l definite ischaemic stroke
l probable ischaemic stroke
l haemorrhagic stroke
l no evidence of stroke.
Revascularisation
For each repeat CABG and PCI recorded on the eCRF, information was collected on whether or not the
procedure was completed as intended. For each revascularisation the following classification was used:
l completed
l not completed.
A further independent committee with two members was set up to review ECGs for all ERICCA patients to
identify unreported PMIs.
Perioperative troponin T
The 72-hour AUC troponin T was assessed by measuring the serum high-sensitivity troponin T (hsTnT)
preoperatively and at 6, 12, 24, 48 and 72 hours after coming off bypass. Six samples were collected per
patient in 5-ml serum-separating tubes (SSTs) or the blood bottle used in the local hospital for measuring
troponin T.
Quantitative hsTnT measurement was performed using a one-step immunoassay based on
electrochemiluminescence technology (Elecsys 2010; Roche, Basel, Switzerland). Internal quality control
was performed on a daily basis with external quality control every 4 weeks. Each hsTnT blood sample was
labelled, centrifuged, divided into two samples, aliquoted, frozen at –20 °C and stored locally. Every
quarter throughtout the recruitment period batches of samples were couriered from the centres to The
Doctors Laboratory in London for analysis.
Inotrope score
The inotrope score provided an objective measurement of the requirement for inotropes in the immediate
postoperative period. Data were collected from the daily medical chart in the ITU. The inotrope score was
calculated at 0 (time when coming off bypass), 24, 48 and 72 hours after surgery. For time 0, the inotrope
score was calculated from the dose of the individual inotrope used at the time of coming off bypass. For
the 24-, 48- and 72-hour time points, the inotrope score was calculated from the maximum dose of the
individual inotropes used in the previous 24 hours:
Inotrope score = dosages (in µg=kg=minute) of ½dopamine + dobutamine + dopeximine
+ ½(adrenaline + noradrenaline + isoproterenol) × 100
+ ½(enoximone +milrinone) × 15
(1)
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Creatinine and acute kidney injury grade
Creatinine was measured at baseline, daily over the 3-day perioperative period and at 6 weeks and 1 year
post CABG. The AKI grade was calculated from the creatinine level measured at baseline during the 3-day
perioperative period. Grades 1–3 were defined as follows:
1. a post-surgery rise of > 26.4 µmol/l or 150–200% of baseline
2. a post-surgery rise of 200–300% of baseline
3. a post-surgery increase of > 300% or post-surgery creatinine > 354 µmol/l associated with a rise from
baseline of at least 44 µmol/l.
Neutrophil gelatinase-associated lipocalin
Neutrophil gelatinase-associated lipocalin in plasma/serum was measured at 6, 12 and 24 hours after
coming off bypass using the NGAL Rapid ELISA Kit (Caltag Medsystems Ltd, Buckingham, UK).
Each NGAL blood sample was labelled and centrifuged and the plasma divided into two samples; these
were then frozen and stored locally at –20 °C. During the recruitment period batches of samples were
couriered quarterly to Caltag Medsystems for analysis.
Duration of intensive therapy unit and hospital stay
This was recorded for the initial hospital admission for cardiac surgery.
Six-minute walk test
The 6MWT was performed at baseline (in the surgical pre-admission clinic 2 weeks before surgery),
at 6 weeks (at the outpatient clinic follow-up appointment) and at 1 year (at the research outpatient clinic
follow-up appointment). Patients were instructed to walk as far as possible along a straight, flat hospital
corridor in 6 minutes.
Quality of life
The EQ-5D three-level health-related quality of life questionnaire was used to assess patient quality of life
post CABG at baseline (in the surgical pre-admission clinic 2 weeks prior to surgery). If an inpatient, this
was collected prior to undergoing CABG. Patient quality of life was assessed again at 6 weeks (at the
surgical outpatient clinic follow-up appointment), 3, 6 and 9 months (by telephone, e-mail or post) and
1 year (at the research outpatient clinic follow-up appointment or by telephone, e-mail or post if unable to
attend in person). Health states from the EQ-5D were converted into health-related quality of life using
UK-based utility weights.42
Genetic and biomarker analysis
A 5-ml SST sample (to obtain serum for biomarker testing) and a 5-ml ethylenediaminetetra-acetic acid
(EDTA) sample (to obtain plasma for biomarker testing and blood for genomic testing) were taken before
RIPC (or sham RIPC) and immediately after RIPC (or sham RIPC). In the biochemistry or pathology
laboratory, once the SST blood bottles had clotted the blood sample was centrifuged at 1300 rpm for
15 minutes and the resultant serum aliquoted into tubes. In the biochemistry or pathology laboratory the
EDTA blood bottles were centrifuged at 1300 rpm for 15 minutes and the resultant plasma aliquoted into
aliquot tubes and frozen at –20 °C. The EDTA blood tubes containing the residual blood were then frozen
at –20 °C.
Every quarter throughout the recruitment period batches of samples were couriered to University College
London (UCL) for analysis.
Left ventricular ejection fraction: echo substudy
An echo substudy had been planned to investigate the effect of RIPC on LVEF at 1 year compared with the
control. However, because of logistical issues with recruitment, only 10 patients completed the baseline
and follow-up scan and so this substudy was not completed.
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Sample size
The planned sample size was 1610 patients. This was informed by the SYNTAX study, in which 12.4% of
patients experienced MACCE at 12 months following CABG surgery.3 However, the patients recruited into
the SYNTAX study included lower-risk patients with a mean euroSCORE of 3.8 [standard deviation (SD)
2.7], whereas the patients in the ERICCA trial were higher-risk patients with a euroSCORE of ≥ 5. In
another study of higher-risk patients who all had left main stem coronary lesions, by 12 months 25% had
MACCE (which included some additional neurological criteria).43 Therefore, for the higher-risk CABG with
or without valve surgery patients in the ERICCA trial, the estimated MACCE rate was taken as 20% at
1 year, which means that to detect a 27% relative reduction in this primary end point in the RIPC-treated
group (from 20.0% to 14.6%), with a power of 80% and a significance level of 5%, a sample size of
770 patients was required for each trial arm (1540 in total). To allow for dropouts (4.5% in the SYNTAX
study) the sample size was increased to 1610 patients in total (805 patients each arm).
Statistical analysis
The primary analysis was conducted on an intention-to-treat (ITT) basis with all patients, when information
was available, considered in the groups to which they were randomised. A per-protocol (PP) analysis was
also undertaken including those who received the randomised intervention as specified and in whom
CABG surgery was completed (i.e. including patients for whom all cycles of RIPC or sham RIPC were fully
completed according to protocol and who received CABG surgery).
Primary outcome
The primary analysis was a comparison of the MACCE rate 1 year after CABG with or without valve
surgery between the RIPC arm and the sham arm of the trial. Hazard ratios (HRs) and 95% confidence
intervals (CIs) were calculated using Cox proportional hazards modelling and Kaplan–Meier curves were
produced. The time scale used for survival analysis was time since intervention. This date was taken as the
date of RIPC/sham RIPC if this was attempted, the date of surgery if the RIPC/sham RIPC was not carried
out and the date of randomisation if neither RIPC/sham RIPC nor surgery was carried out. Participants who
did not experience MACCE were censored on the date of non-cardiovascular death, loss to follow-up or
withdrawal from the study or at 12 months. The proportional hazard assumption underlying the Cox
model was assessed graphically and through global test of the scaled Schoenfeld residuals.44
Secondary outcomes
Thirty-day major adverse cardiac and cerebral events, components of 30-day
and 12-month major adverse cardiac and cerebral events, definite major
adverse cardiac and cerebral events and all-cause death at 12 months
Cox proportional hazards models were used to evaluate 30-day MACCE; components of 30-day and
12-month MACCE; and all-cause death at 12 months. Definitions of start of follow-up and censoring were
as described for the analysis of the primary outcome.
Seventy-two-hour area under the curve troponin T
Differences in mean PMI (72-hour AUC troponin T) were assessed using a simple linear regression model
for the natural logarithm of the AUC, with results expressed as a ratio of the geometric means. A log
transform was used to provide a better approximation to the normal distribution as this outcome showed
substantial skew.
Acute kidney injury score after 72 hours
Acute kidney injury grade was compared between the two groups using a non-parametric test for trend.
METHODS
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Inotrope score after 72 hours
Inotrope score was compared between groups using the non-parametric Wilcoxon rank sum test.
Serum creatinine level at baseline, 6 weeks and 12 months
Analysis of covariance (ANCOVA), adjusting for baseline values, was used to compare the RIPC arm and
the sham arm in terms of the natural logarithm of serum creatinine at 6 weeks and 12 months. Serum
creatinine was log transformed for analysis because it showed substantial skew.
Twenty-four-hour area under the curve neutrophil gelatinase-associated
lipocalin
Differences in mean 24-hour AUC NGAL were assessed using a simple linear regression model for the
natural logarithm of the AUC, with the results expressed as a ratio of the geometric means. A log
transform was used to provide a better approximation to the normal distribution because of
substantial skew.
Length of intensive therapy unit stay and hospital stay
Competing-risk proportional hazards models45 were used to compare groups with regard to hospital stay
and ITU stay. These models were used to account for censoring because of the competing risk of death
before discharge or end of ITU, respectively.
Six-minute walk test
A linear mixed model was used to compare the mean distance walked in the 6MWT between the RIPC
arm and the sham arm at 6 weeks and 12 months. Distance walked at baseline was treated as an
additional time point in the outcome model with treatment effect constrained to zero, making this analysis
essentially equivalent to an analysis of covariance, adjusting for baseline.
Health status and self-rated health
Analysis of covariance, adjusting for baseline values, was used to compare the RIPC and sham arms with
regard to mean health status and self-rated health at 6 weeks and 3, 6, 9 and 12 months. Health status
and self-rated health showed substantial departures from a normal distribution that were still apparent
after transformation, so inference was based on non-parametric, bias-corrected and accelerated bootstrap
CIs, which were calculated from 2000 replications stratified by treatment group.
Post-surgery atrial fibrillation
Logistic regression was used to compare the RIPC and sham groups with regard to the proportion with
postoperative AF, which was a post hoc outcome.
Missing data
Initial models used complete case analysis and so included only participants with full data, which assumes
that outcomes are missing at random given the treatment group. For analysis of AUC troponin T and AUC
NGAL this required participants to have data available for all time points, and for analysis of serum
creatinine this required participants to have data available at baseline and at the relevant follow-up visit.
As a large number of participants were excluded from the complete case analysis of these outcomes,
further imputation analysis was conducted to examine whether or not these missing data had an impact
on the findings.
Multiple imputation was used to replace any missing values of troponin T, NGAL and serum creatinine.
Data were imputed on the natural logarithm scale for each time point using Gaussian normal regression
multiple imputation by chained equations. Twenty imputed data sets were generated using a separate
imputation model for troponin T, NGAL and serum creatinine. Variables collected at baseline or during
follow-up were included in the imputation model in which they were independent predictors of a
participant having missing data (assessed using logistic regression models) or were predictive of the values
of the outcome (assessed using linear regression).
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The imputation model for natural logarithm of troponin T included log of troponin T at each time point
(baseline and 6, 12, 24, 48 and 72 hours); treatment group; sex; baseline euroSCORE, New York Heart
Association (NYHA) class, Canadian Cardiovascular Society angina class, LVEF class, smoking status,
age, natural logarithm of creatinine, diastolic blood pressure and heart rate; previous use of aspirin,
beta-blockers, nitrates, diuretics, clopidogrel and metformin; previous diagnosis of MI, peripheral arterial
disease and hypercholesterolaemia; bypass duration; use of cardioplegia during surgery; use of nitrates
during surgery; number of grafts; post-surgical outcomes of number of days in ITU, requirement for cardiac
pacing, renal failure and AKI; and death from cardiovascular causes within 12 months of surgery.
The imputation model for natural logarithm of NGAL included log of NGAL at each time point (baseline
and 6, 12 and 24 hours); treatment group; sex; baseline euroSCORE, natural logarithm of creatinine,
age and diastolic blood pressure; previous use of aspirin, nitrates, cholesterol-lowering medication,
angiotensin-converting enzyme inhibitors/angiotensin receptor antagonists; previous diagnosis of diabetes;
previous PCI; bypass duration; use of cardioplegia during surgery; valve repair/replacement; post-surgical
outcomes of number of days in ITU, AF, renal failure and AKI; and death from cardiovascular causes within
12 months of surgery.
The imputation model for natural logarithm of serum creatinine included log of creatinine at each time
point (baseline, 6 weeks and 12 months); treatment group; sex; baseline euroSCORE, NYHA class, LVEF
class, age, heart rate, diastolic blood pressure and body mass index; previous use of aspirin, nitrates,
diuretics, sulphonylureas, metformin and insulin; previous diagnosis of stroke; and post-surgical outcomes
of AF and AKI.
The multiple imputation analysis for all outcomes excluded 15 participants who did not have any baseline
data and one patient who was randomised but following enrolment was found not to meet the eligibility
criteria for the trial. Analysis additionally excluded any patients who died before the outcome could have
been collected: 16 patients for 72-hour AUC hsTnT; 11 patients for 24-hour AUC NGAL; 57 patients for
creatinine at 6 weeks; and 125 patients for creatinine at 12 months. All other patients were included in
the imputation analyses.
Subgroup analyses
Subgroup analysis were conducted to assess if the effect of RIPC on MACCE differed according to age,
baseline euroSCORE, baseline LVEF, aortic cross-clamp time, cardiac bypass time, method of cardioplegia
and presence/absence of diabetes. Each subgroup was assessed through a Wald test of the interaction
between the subgroup variable and treatment group in the Cox proportional hazards model. The
subgroup variable was entered as a continuous variable for age, euroSCORE, clamp time and bypass time
and as a categorical variable for LVEF class (normal/good vs. moderate vs. poor) and diabetes (binary: yes
vs. no). Two post hoc subgroup analyses were carried out for the time interval between the start of RIPC
and the end of bypass (continuous) and the type of anaesthetic used during surgery (binary: volatiles with
or without propofol vs. propofol with no use of volatiles). When subgroup variables were continuous we
provide the numbers with events and HRs and 95% CIs for RIPC treatment among those above and those
below the median level of the subgroup variable. Otherwise, results are given for each category of
the subgroup.
Ethical considerations
Ethical approval for the study in the UK was given in October 2010 by the East London 3 Research Ethics
Committee (reference number 10/H0701/111). The trial was registered with a National Clinical Trial
number of NCT01247545. The trial had two committees overseeing its conduct: the Trial Steering
Committee (TSC) and the Project Management Group. In addition, there was an independent DMC to
ensure the safety of patients in the trial and review operational issues such as recruitment. The DMC was
the only group to review interim analyses broken down by treatment groups during recruitment and
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
follow-up of patients in the trial. The DMC performed interim safety analyses annually. The interim reports
contained details of patient recruitment, demographic and baseline characteristics, the CABG surgery and
intervention, primary safety end points, the primary efficacy end point and other end points identified by
the DMC including adverse and serious adverse events (SAEs).
The TSC had overall responsibility for the scientific integrity and quality of the trial. This involved
conduction of the trial to the standards set out in the guidelines for Good Clinical Practice,39 adherence to
the protocol as far as possible and responsibility for overall patient safety as well as consideration of new
relevant information arising throughout the duration of the trial. The TSC was also responsible for
considering any recommendations made by the DMC. The TSC met annually throughout the ERICCA trial
to monitor the progress and quality of the trial (review the recruitment rate and consider protocol
amendments). The Project Management Group was responsible for the day-to-day running of the trial,
meeting fortnightly during the setting up of the ERICCA trial and the early stages of recruitment and then
approximately monthly for the remainder of the trial.
Patient and consumer involvement
Three consumers were actively involved as members of the TSC. The consumers were recruited from the
rehabilitation group that was run at UCL for patients who had undergone CABG surgery. Although not all
of them were able to attend all of the TSC meetings, there was always one representative of the three
present. They all, however, contributed to and commented on any ERICCA literature, including the patient
information sheet or newsletters.
One of the consumers was very actively involved in the trial and helped produce a training video on how
to administer RIPC [see www.youtube.com/watch?v = SsX3atcc08M (accessed 5 June 2016)]. This was also
available on digital versatile disc. This consumer was invited to the investigator meetings and was very
active in discussing the trial.
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Chapter 3 Results
Between April 2011 and March 2014, 1612 patients undergoing on-pump CABG (with or without valve)surgery were recruited to the ERICCA trial from 30 study sites. Figure 1 shows the number of patients
randomised to each treatment arm along with the numbers completing the intervention and losses to
follow-up. Detailed screening logs of 1 month’s duration were obtained for 3 separate months out of the
36-month recruitment period. Out of 1869 patients screened during the 3 months, 414 (22.2%) patients
were found to be eligible for inclusion in the study, of whom 195 (47.1%) were randomised into the
study. A euroSCORE of < 5 was the main reason for patient ineligibility.
Patients attended a clinic visit at the time of randomisation and at 6 weeks and 12 months following
surgery. Information on the primary outcome MACCE was collected during the first 12 months following
surgery, with the last follow-up in May 2015.
Allocated to sham control
(n = 811)
• Received allocated intervention, n = 717
• Did not receive allocated intervention, n = 71
   • CABG not done, n = 29
   • Staff not available, n = 27
   • Medical reason, n = 5
   • Patient not eligible, n = 4
   • Theatre staff did not consent, n = 1
   • Patient withdrew consent, n = 4
   • Unknown reason, n = 1
• Partially received allocated intervention, n = 23
   • Interrupted by preparations for surgery, n = 9
   • Mechanical failure of cuff, n = 0
   • Medical reason, n = 1
   • Intervention incorrectly given, n = 13
Lost to follow-up before 12-month visit
(n = 83)
• Death, n = 55
• CABG not done, patient withdrawn, n = 2
• Withdrew consent, n = 17
• Withdrawn, n = 2
• Lost to follow-up, n = 7
Analysed
(n = 811)
Allocated to RIPC
(n = 801)
• Received allocated intervention, n = 691
• Did not receive allocated intervention, n = 79
   • CABG not done, n = 23
   • Staff not available, n = 26
   • Medical reason, n = 15
   • Patient not eligible, n = 4
   • Theatre staff did not consent, n = 3
   • Patient withdrew consent, n = 7
   • Unknown reason, n = 1
• Partially received allocated intervention, n = 31
   • Interrupted by preparations for surgery, n = 17
   • Mechanical failure of cuff, n = 3
   • Medical reason, n = 6
   • Intervention incorrectly given, n = 5
Lost to follow-up before 12-month visit
(n = 90)
• Death, n = 71
• CABG not done, patient withdrawn, n = 1
• Withdrew consent, n = 13
• Withdrawn, n = 1
• Lost to follow-up, n = 4
Analysed
(n = 801)
Randomised
(n = 1612)
Allocation
Follow-up
Analysis
FIGURE 1 Consolidated Standards of Reporting Trial (CONSORT) diagram.
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The treatment groups were well balanced in respect of both patient baseline characteristics (Table 1) and
surgical details (Table 2). Table 1 does not include data for all patients randomised in the study as some
patients were withdrawn from the study; some patients did not have CABG surgery or the intervention
performed; and some patients’ notes were unavailable or it was not possible to track the notes down or
data were not recorded in the notes. Use of cardiovascular medications was similar in the two treatment
groups at baseline, on discharge from hospital and at the 6-week and 12-month follow-up visits (Table 3).
TABLE 1 Patient baseline characteristicsa
Characteristic Sham control (N= 811) RIPC (N= 801)
Male, n (%) 586 (72.7) 556 (70.4)
Age (years), mean (SD)b 76.3 (7.0) 76.1 (6.1)
euroSCORE, median (minimum–maximum) 6 (5–16) 6 (5–17)
BMI (kg/m2), mean (SD) 27.5 (4.3) 27.7 (4.6)
Smoking status (ex/current), n (%) 525 (65.1) 504 (63.8)
Creatinine (µmol/l), mean (SD) 94.8 (35.2) 94.3 (27.2)
Previous diagnoses, n (%)c
Diabetes 211 (26.1) 203 (25.7)
Hypercholesterolaemia 555 (68.8) 570 (72.2)
Hypertension 599 (74.2) 602 (76.2)
MI 309 (38.3) 328 (41.5)
Stroke 89 (11.0) 95 (12.0)
AF 145 (18.0) 117 (14.8)
Peripheral arterial disease 62 (7.7) 59 (7.5)
Previous PCI 121 (15.0) 115 (14.6)
Previous CABG 19 (2.4) 27 (3.4)
LVEF, n/N (%)
Good (> 50%) 515/767 (67.1) 497/741 (67.1)
Moderate (31–50%) 158/767 (20.6) 163/741 (22.0)
Poor (< 30%) 94/767 (12.3) 81/741 (10.9)
NYHA class, n (%)
No symptoms 118 (14.6) 121 (15.3)
I 108 (13.4) 108 (13.7)
II 327 (40.6) 336 (42.5)
III 241 (29.9) 208 (26.3)
IV 12 (1.5) 17 (2.2)
CCS angina class, n (%)
No symptoms 262 (32.5) 212 (26.8)
I 142 (17.6) 118 (14.9)
II 223 (27.7) 270 (34.2)
III 128 (15.9) 119 (15.1)
IV 51 (6.3) 71 (9.0)
BMI, body mass index; CCS, Canadian Cardiovascular Society.
a Data available for 806 sham control and 790 RIPC participants unless otherwise stated.
b Data available for all participants.
c Data available for 807 sham control and 790 RIPC participants.
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TABLE 2 Details of surgery
Surgery Sham control (N= 811) RIPC (N= 801)
CABG surgery completed, n/N (%) 776/805 (96.4) 772/789 (97.8)
One graft 178/776 (22.9) 148/772 (19.2)
Two grafts 193/776 (24.9) 180/772 (23.3)
Three grafts 295/776 (38.0) 328/772 (42.5)
Four or more grafts 109/776 (14.0) 116/772 (15.0)
Valve surgery, n/N (%) 406/775 (52.4) 371/772 (48.1)
Cross-clamp time (minutes), median (minimum–maximum)a 71 (15 to 292) 69 (18 to 324)
CPB time (minutes), median (minimum–maximum)b 107 (29 to 422) 105 (34 to 585)
Time between start of RIPC and initiation of bypass (hours), mean (SD)c 1.75 (0.64) 1.72 (0.65)
Anaesthetic type, n (%)d
Volatile, without propofol 11 (1.4) 12 (1.6)
Volatile, with propofol 312 (40.7) 313 (40.7)
Propofol, without volatile 397 (51.8) 409 (53.2)
Other: no propofol or volatile 47 (6.1) 35 (4.6)
Perioperative agents, n (%)d
Atracurium 23 (3.0) 28 (3.6)
Cisatracurium 3 (0.4) 2 (0.3)
Desflurane 1 (0.1) 0 (0.0)
Diazepam 11 (1.4) 20 (2.6)
Lorazepam 0 (0.0) 1 (0.1)
Ketamine 1 (0.1) 0 (0.0)
Lignocaine 0 (0.0) 1 (0.1)
Nitrous oxide 2 (0.3) 1 (0.1)
Oxycodone 1 (0.1) 1 (0.1)
Pethidine 2 (0.3) 0 (0.0)
Remifentanil 77 (10.0) 82 (10.7)
Suxamethonium 3 (0.4) 2 (0.3)
Thiopentone 20 (2.6) 21 (2.7)
Tramadol 1 (0.1) 0 (0.0)
Fentanyl 674 (87.9) 668 (86.9)
Midazolam 494 (64.4) 494 (64.2)
Isoflurane 310 (40.4) 312 (40.6)
Morphine 236 (30.8) 241 (31.3)
Etomidate 84 (11.0) 85 (11.1)
Propofol 709 (92.4) 722 (93.9)
Pancuronium 241 (31.4) 252 (32.8)
Vecuronium 46 (6.0) 52 (6.8)
continued
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TABLE 2 Details of surgery (continued )
Surgery Sham control (N= 811) RIPC (N= 801)
Glycopyrrolate 29 (3.8) 27 (3.5)
Paracurium 10 (1.3) 6 (0.8)
Rocuronium 420 (54.8) 410 (53.3)
Bevicuronium 7 (0.9) 1 (0.1)
Alfentanil 52 (6.8) 49 (6.4)
Sevoflurane 18 (2.3) 17 (2.2)
IV nitrates, n/N (%) 230/775 (29.7) 233/772 (30.2)
CPB, cardiopulmonary bypass; IV, intravenous.
a Data available for 734 sham control and 735 RIPC participants.
b Data available for 707 sham control and 704 RIPC participants.
c Data available for 750 sham control and 757 RIPC participants.
d Data available for 767 sham control and 769 RIPC participants.
TABLE 3 Cardiovascular medication use [n (%)] at baseline, discharge from hospital, 6 weeks’ follow-up and
12 months’ follow-up
Medication Sham control (N= 811) RIPC (N= 801)
Baseline
n 807 791
Aspirin 635 (78.7) 629 (79.5)
Beta-blocker 516 (63.9) 515 (65.1)
Calcium channel blocker 222 (27.5) 239 (30.2)
Nitrates 253 (31.4) 255 (32.2)
Cholesterol-lowering agents 698 (86.5) 670 (84.7)
Statins 652 (80.8) 633 (80.0)
Other cholesterol-lowering agents 7 (0.9) 5 (0.6)
Both statins and other cholesterol-lowering agents 6 (0.7) 2 (0.3)
Unspecified 33 (4.1) 30 (3.8)
ACE inhibitor/AT2 antagonist 473 (58.6) 499 (63.1)
Insulin 59 (7.3) 50 (6.3)
Sulphonylurea 49 (6.1) 42 (5.3)
Metformin 137 (17.0) 135 (17.1)
Clopidogrel 177 (21.9) 208 (26.3)
Warfarin 98 (12.1) 89 (11.3)
Diuretics 327 (40.5) 290 (36.7)
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TABLE 3 Cardiovascular medication use [n (%)] at baseline, discharge from hospital, 6 weeks’ follow-up and
12 months’ follow-up (continued )
Medication Sham control (N= 811) RIPC (N= 801)
At discharge from hospital
n 784 766
Aspirin 698 (89.0) 671 (87.6)
Beta-blocker 592 (75.5) 579 (75.6)
Calcium channel blocker 103 (13.1) 87 (11.4)
Nitrates 7 (0.9) 9 (1.2)
Cholesterol-lowering agents 678 (86.5) 677 (88.4)
Statins 659 (84.1) 667 (87.1)
Other cholesterol-lowering agents 11 (1.4) 5 (0.7)
Both statins and other cholesterol-lowering agents 7 (0.9) 5 (0.7)
Unspecified 1 (0.1) 0 (0.0)
ACE inhibitor/AT2 antagonist 383 (48.9) 380 (49.6)
Insulin 50 (6.4) 52 (6.8)
Sulphonylurea 40 (5.1) 31 (4.0)
Metformin 118 (15.1) 128 (16.7)
Clopidogrel 168 (21.4) 180 (23.5)
Warfarin 168 (21.4) 161 (21.0)
Diuretics 492 (62.8) 523 (68.3)
6 weeks’ follow-up
n 776 758
Aspirin 647 (83.4) 629 (83.0)
Beta-blocker 584 (75.3) 559 (73.7)
Calcium channel blocker 101 (13.0) 92 (12.1)
Nitrates 12 (1.5) 19 (2.5)
Cholesterol-lowering agents 658 (84.8) 656 (86.5)
Statins 643 (82.9) 648 (85.5)
Other cholesterol-lowering agents 9 (1.2) 3 (0.4)
Both statins and other cholesterol-lowering agents 6 (0.8) 5 (0.7)
Unspecified 0 (0.0) 0 (0.0)
ACE inhibitor/AT2 antagonist 398 (51.3) 397 (52.4)
Insulin 41 (5.3) 48 (6.3)
Sulphonylurea 36 (4.6) 33 (4.4)
Metformin 112 (14.4) 121 (16.0)
Clopidogrel 146 (18.8) 154 (20.3)
Warfarin 168 (21.6) 162 (21.4)
Diuretics 394 (50.8) 414 (54.6)
continued
DOI: 10.3310/eme03040 EFFICACY AND MECHANISM EVALUATION 2016 VOL. 3 NO. 4
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hausenloy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
21
The intervention was completed according to protocol for 716 (88%) of the sham control participants and
691 (86%) of the RIPC participants, with reasons for incomplete intervention given in Figure 1. The mean (SD)
time between the start of RIPC and initiation of bypass was 1.75 hours (0.64 hours) in the sham control group
and 1.72 hours (0.65 hours) in the RIPC group. There were very few participants lost to follow-up before
12 months: 28 (3%) losses to follow-up for reasons other than death in the sham control group and 19 (2%)
in the RIPC group (see Figure 1). All 1612 patients were included in the analysis of the primary outcome.
Effect of remote ischaemic preconditioning on major adverse
cardiac and cerebral events
The proportion of participants with the MACCE primary end point within 12 months was similar between
the groups [RIPC group 26.5% (n= 212) vs. control group 27.7% (n= 225); HR 0.95, 95% CI 0.79 to
1.15; p= 0.58)] (Table 4 and Figure 2). There was no evidence of a difference between the sham control
group and the RIPC group in any of the individual components of MACCE (cardiovascular death, MI,
stroke and coronary revascularisation) (see Table 4). The results of the PP analysis were very similar to those
of the ITT analysis and showed little difference in the incidence of MACCE between the RIPC group and
the sham control group. In the PP analysis 27.2% (n= 188/691) of participants in the RIPC group
experienced MACCE within 12 months compared with 28.5% (n= 204/717) of participants in the sham
control group (HR 0.95, 95% CI 0.78 to 1.16; p= 0.64) (Table 5).
TABLE 3 Cardiovascular medication use [n (%)] at baseline, discharge from hospital, 6 weeks’ follow-up and
12 months’ follow-up (continued )
Medication Sham control (N= 811) RIPC (N= 801)
12 months’ follow-up
n 742 719
Aspirin 566 (76.3) 556 (77.3)
Beta-blocker 531 (71.6) 525 (73.0)
Calcium channel blocker 119 (16.0) 103 (14.3)
Nitrates 28 (3.8) 37 (5.1)
Cholesterol-lowering agents 625 (84.2) 615 (85.5)
Statins 614 (82.7) 598 (83.2)
Other cholesterol-lowering agents 8 (1.1) 8 (1.1)
Both statins and other cholesterol-lowering agents 3 (0.4) 5 (0.7)
Unspecified 0 (0.0) 4 (0.6)
ACE inhibitor/AT2 antagonist 437 (58.9) 422 (58.7)
Insulin 40 (5.4) 40 (5.6)
Sulphonylurea 29 (3.9) 28 (3.9)
Metformin 107 (14.4) 116 (16.1)
Clopidogrel 102 (13.7) 112 (15.6)
Warfarin 141 (19.0) 121 (16.8)
Diuretics 283 (38.1) 255 (35.5)
ACE, angiotensin-converting enzyme; ATZ, angiotensin receptor.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
TABLE 4 Effect of RIPC on MACCE at 30 days and 12 months after transplantation, definite MACCE within
12 months and death from any cause within 12 months: ITT analysis
Outcome
n (%) with event
in sham control
group (N= 811)
n (%) with event in
RIPC group (N= 801)
HR (sham control
vs. RIPC) (95% CI) p-value
Primary end point
MACCE within 12 months 225 (27.7) 212 (26.5) 0.95 (0.79 to 1.15) 0.58
Cardiovascular death 32 (3.9) 47 (5.9) 1.50 (0.96 to 2.35) 0.08
MI 191 (23.6) 173 (21.6) 0.91 (0.74 to 1.12) 0.39
Stroke 16 (2.0) 17 (2.1) 1.08 (0.55 to 2.14) 0.82
Coronary revascularisation 3 (0.4) 2 (0.2) 0.68 (0.11 to 4.09) 0.68
Secondary end points
Definite MACCE within
12 monthsa
93 (11.5) 104 (13.0) 1.13 (0.86 to 1.50) 0.38
MACCE within 30 days 206 (25.4) 186 (23.2) 0.91 (0.75 to 1.11) 0.36
Cardiovascular death 20 (2.5) 24 (3.0) 1.22 (0.67 to 2.20) 0.52
MI 188 (23.2) 168 (21.0) 0.90 (0.73 to 1.11) 0.34
Stroke 10 (1.2) 10 (1.2) 1.01 (0.42 to 2.44) 0.98
Coronary revascularisation 0 (0) 0 (0)
Death within 12 months 54 (6.7) 69 (8.6) 1.31 (0.92 to 1.87) 0.14
a Includes cardiovascular death, coronary revascularisation, definite MIs and definite strokes. Excludes probable MIs and
probable strokes.
Sham control 225 events (27.7%)
RIPC 212 events (26.5%)
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FIGURE 2 Cumulative incidence of MACCE up to 12 months.
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Subgroup analysis for major adverse cardiac and cerebral events
There was no evidence that the effect of the RIPC intervention differed between any of the prespecified
subgroup analyses for the incidence of MACCE at 12 months (Figure 3). Although a subgroup analysis was
planned by type of cardioplegia, only 19 participants had retrograde cardioplegia and so this subgroup
analysis was not conducted. The other post hoc subgroup analyses found no evidence that the effect of
RIPC on MACCE differed by the type of anaesthetic used during surgery (p= 0.17 interaction test) or by
the duration between the start of RIPC and the initiation of bypass (p= 0.66 interaction test).
TABLE 5 Effect of RIPC on MACCE at 30 days and 12 months after transplantation and definite MACCE within
12 months: PP analysis
Outcome
n (%) with event
in sham control
group (N= 717)
n (%) with event in
RIPC group (N= 691)
HR (sham vs. RIPC)
(95% CI) p-value
Primary end point
MACCE within 12 months 204 (28.5) 188 (27.2) 0.95 (0.78 to 1.16) 0.64
Cardiovascular death 26 (3.6) 40 (5.8) 1.61 (0.98 to 2.64) 0.06
MI 177 (24.7) 156 (22.6) 0.91 (0.74 to 1.13) 0.41
Stroke 14 (2.0) 15 (2.2) 1.12 (0.54 to 2.32) 0.76
Coronary revascularisation 3 (0.4) 2 (0.3) 0.70 (0.12 to 4.18) 0.70
Secondary end points
Definite MACCE within 12 monthsa 83 (11.6) 94 (13.6) 1.18 (0.88 to 1.58) 0.28
MACCE within 30 days 187 (26.1) 168 (24.3) 0.93 (0.76 to 1.15) 0.50
Cardiovascular death 16 (2.2) 22 (3.2) 1.43 (0.75 to 2.73) 0.27
MI 174 (24.3) 153 (22.1) 0.91 (0.73 to 1.13) 0.41
Stroke 8 (1.1) 9 (1.3) 1.17 (0.45 to 3.04) 0.74
Coronary revascularisation 0 (0.0) 0 (0.0)
a Includes cardiovascular death, coronary revascularisation, definite MIs and definite strokes. Excludes probable MIs and
probable strokes.
RESULTS
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Effect of remote ischaemic preconditioning on
secondary outcomes
Complete case analysis of the 728 of 1612 patients (45%) with full data on PMI suggested that there was
a 10% lower AUC hsTnT in patients undergoing RIPC than in sham control patients (Table 6). This effect
largely disappeared when multiple imputation analyses were undertaken (2% reduction, 95% CI 9%
reduction to 6% increase; p= 0.63). This lack of effect was supported by examination of the data for 1282
of 1612 patients (80%) who had at least one perioperative hsTnT result, which showed little difference at
any time point between the RIPC group and the sham control group (Figure 4). Post hoc subgroup
analyses found no evidence that the effect of RIPC on PMI differed by the type of anaesthetic used during
surgery or by the duration between the start of RIPC and the initiation of bypass (Table 7).
Participants in the RIPC arm had a further walk distance than sham control participants on the 6MWT at
12 months, although this finding should be interpreted with caution, as only 785 participants completed
the 6MWT on one or more occasions (baseline, 6 weeks or 12 months) and, of these, only 360 participants
completed the 6MWT at 12 months (Table 8). There was no evidence of any effect of RIPC on any of the
other secondary end points (Tables 8–10). Although an echocardiography substudy had been planned,
because of logistical issues very few patients were included in the study and so no meaningful data on LVEF
were available for analysis.
TABLE 6 Effect of RIPC on 72-hour AUC hsTnT, 24-hour AUC NGAL and serum creatinine: ITT analysis
Outcome
Sham control
(N= 811) RIPC (N= 801)
Ratio of geometric means
(sham control vs. RIPC)
(95% CI) p-value
72-hour AUC hsTnT (ng.h/ml)
Median (IQR) 35.7 (22.8–57.3) 30.1 (20.3–53.9)
Complete cases, n 367 361 0.90 (0.81 to 0.99) 0.031
Multiple imputation, n 798 782 0.98 (0.91 to 1.06) 0.63
Serum creatinine 6 weeks (µmol/l)
Median (IQR) 90 (76–109) 92 (75–111)
Complete cases, n 397 368 1.01 (0.98 to 1.04) 0.64
Multiple imputation, n 782 757 1.01 (0.98 to 1.04) 0.67
Serum creatinine 12 months (µmol/l)
Median (IQR) 93 (81–113) 91 (79–111)
Complete cases, n 320 320 0.98 (0.95 to 1.01) 0.26
Multiple imputation, n 752 719 0.97 (0.95 to 1.00) 0.06
24-hour AUC NGAL (ng.h/ml)
Median (IQR) 7293 (5310–10,436) 7148 (5318–10,389)
Complete cases, n 541 544 0.99 (0.93 to 1.05) 0.652
Multiple imputation, n 800 785 0.99 (0.94 to 1.05) 0.785
IQR, interquartile range.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
6 12 24 48 72
Hours post surgery
0.01
0.10
1.00
10.00
(a)
h
sT
n
T 
(n
g
.h
/m
l)
0.01
0.10
1.00
10.00
h
sT
n
T 
(n
g
.h
/m
l)
(b)
6 12 24 48 72
Hours post surgery
FIGURE 4 Box plot of the median, lower quartile, upper quartile, minimum and maximum for hsTnT at each time
point for (a) all participants; and (b) participants with complete data. Sham control shown in green, RIPC in blue.
Number of observations: (a) 1186 at 6 hours, 1171 at 12 hours, 1209 at 24 hours, 1082 at 48 hours and 937 at
72 hours; and (b) 728 at all time points.
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TABLE 7 Post hoc subgroup analyses for the effect of RIPC on 72-hour AUC hsTnT (ng.h/ml)
Subgroup
Sham control
(N= 811) RIPC (N= 801)
Ratio of geometric means
(95% CI)
Interaction
p-value
Anaesthetics, median (IQR)
Volatile, with or without
propofol
35.7 (23.0 to 54.7) 29.2 (19.1 to 51.5)
Propofol, without volatile 35.9 (22.0 to 63.9) 32.8 (22.4 to 58.3)
Complete case analysis, n
Volatile, with or without
propofol
178 183 0.88 (0.77 to 1.02) 0.728
Propofol, without volatile 156 161 0.92 (0.79 to 1.07)
Multiple imputation analysis, na
Volatile, with or without
propofol
321 320 0.94 (0.84 to 1.06) 0.453
Propofol, without volatile 393 405 1.01 (0.90 to 1.13)
Interval between start of RIPC and end of bypass (hours), median (IQR)
0.4 to < 1.7 36.0 (24.4–57.2) 31.6 (21.7–53.9)
1.7 to 8.4 35.7 (22.1–58.9) 28.9 (19.5–55.2)
Complete case analysis, n
0.4 to < 1.7 169 177 0.98 (0.79 to 1.04) 0.633
1.7 to 8.4 174 170 0.87 (0.76 to 1.01)
Multiple imputation analysis, na
0.4 to < 1.7 355 359 1.01 (0.90 to 1.13) 0.303
1.7 to 8.4 346 336 0.95 (0.85 to 1.06)
IQR, interquartile range.
a To allow for the potential for an interaction between treatment and the subgroup variable the multiple imputation was
stratified by treatment group and the subgroup variable included in the imputation models for natural logarithm hsTnT
at each time point (baseline and 6, 12, 24, 48 and 72 hours) along with the previously specified variables. In all other
regards the multiple imputation analyses followed the previously described methods.
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TABLE 8 Effect of RIPC on 6MWT and quality of life: ITT analysis
Outcome Sham control (N= 811) RIPC (N= 801) Difference in means (95% CI) p-value
6MWT distance (metres), mean (SD)
6 weeks 335 (125) 332 (109) –3.8 (–24.4 to 16.8) 0.72
12 months 365 (128) 386 (116) 23.3 (2.2 to 44.4) 0.031
n 402 383
EQ-5D health status, mean (SD) NAa
6 weeks 0.74 (0.27) 0.73 (0.29) –0.02 (–0.053 to 0.006)
n 689 682
3 months 0.78 (0.26) 0.78 (0.27) –0.01 (–0.037 to 0.015)
n 698 693
6 months 0.78 (0.28) 0.78 (0.30) –0.01 (–0.036 to 0.021)
n 704 685
9 months 0.78 (0.28) 0.78 (0.30) –0.01 (–0.035 to 0.023)
n 694 690
12 months 0.77 (0.29) 0.76 (0.31) –0.03 (–0.056 to 0.004)
n 703 706
EQ-5D thermometer self-rated health index, mean (SD) NAa
6 weeks 72 (17) 73 (17) 0.6 (–1.1 to 2.3)
n 662 647
3 months 76 (16) 76 (16) –0.3 (–1.8 to 1.5)
n 673 650
6 months 78 (16) 79 (16) 0.9 (–0.6 to 2.6)
n 662 631
9 months 79 (16) 80 (15) 0.6 (–1.1 to 2.2)
n 646 625
12 months 80 (16) 80 (16) –0.4 (–2.1 to 1.3)
NA, not applicable.
a p-value not applicable as inference based on non-parametric, bias-corrected and accelerated bootstrap 95% CIs.
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A total of 1085 out of 1612 (67%) patients with full data on NGAL were included in the complete case
analysis; of these, 1411 out of 1612 (88%) patients had at least one NGAL result, including pre-operative
samples. The majority of patients had at least one perioperative result (1318/1612, 82%). The proportions
with data were balanced between the treatment arms: 669 out of 811 (82%) patients in the sham control
arm and 649 out of 801 (81%) in the RIPC arm. The number of results available at individual time points
was between 1206 out of 1612 (75%) at 12 hours and 1356 out of 1612 (84%) preoperatively, with fairly
similar numbers of patients with data in the two treatment arms at any given time point. Of the 779
participants with creatinine recorded at 6 weeks, nearly all (765/779, 98%) also had baseline data and so
were included in the complete case analysis. Similarly, there were 651 participants with creatinine recorded
at 12 months, and 640 out of 1612 (40%) had data available at both baseline and 12 months and so
were included in the complete case analysis. As most patients with data at a given time point were
included in the complete case analysis for creatinine, it is not meaningful to compare serum creatinine
between those who were included and those who were excluded from this analysis. However, it can be
seen that the patterns of creatinine at other time points was generally similar in those with and without
any missing data. Values at 12 months were slightly higher in the control than RIPC arm in both the
participants included in and those excluded from the 6 weeks’ complete case analysis. There was little
difference between the RIPC and control arm in values at 6 weeks in both participants who were included
and participants who were excluded from the 12 months’ analysis: 90 µmol/l control versus 89 µmol/l RIPC
in those excluded from the complete case and 93 µmol/l control versus 93 µmol/l RIPC in those included in
the complete case analysis.
TABLE 9 Effect of RIPC on inotrope score, hospital stay, ITU stay and AKI: ITT analysis
Outcome Sham control (N= 811) RIPC (N= 801) p-value
Inotrope score
Median (IQR) 6 (0–16) 6 (0–15) 0.917
n 794 775
Hospital stay (days)
Median (IQR) 10 (7–17) 10 (7–16) 0.363
n 775 758
ITU stay (days)
Median (IQR) 3 (1–5) 2 (1–4) 0.346
n 775 758
AKI, n/N (%) 293/772 (38.0) 287/749 (38.3) 0.975
Grade 1 226/772 (29.3) 230/749 (30.7)
Grade 2 44/772 (5.7) 38/749 (5.1)
Grade 3 23/772 (3.0) 19/749 (2.5)
IQR, interquartile range.
TABLE 10 Effect of RIPC on postoperative AF: ITT analysis
Outcome
n/N (%) with event in sham
control group (N= 811)
n/N (%) with event in RIPC
group (N= 801)
Odds ratio (sham vs.
RIPC) (95% CI) p-value
Postoperative AFa 314/794 (39.5) 305/779 (39.2) 0.98 (0.80 to 1.20) 0.873
a Post hoc outcome; not prespecified in the statistical analysis plan.
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Adverse events
The number of adverse events was similar between the RIPC group and the sham control group [364/801
(45%) vs. 354/811 (44%), respectively] (Table 11). More participants in the RIPC group than in the sham
control group experienced skin petechiae at the time of the intervention [35/801 (4.4%) vs. 2/811 (0.2%),
respectively], with no long-term consequences. Three unexpected adverse events occurred at the time of
the RIPC/sham control intervention. Only one of these was thought to be related to the intervention –
the blood pressure cuff used in the RIPC intervention remained inflated during surgery, but this had no
long-term consequences. A similar proportion in the RIPC and sham control groups experienced adverse
events at times other than during the RIPC/sham control intervention [349/801 (44%) vs. 353/811 (44%),
respectively], but none of these was thought to be related to the intervention. Although there was a trend
towards an increase in the rate of cardiovascular death in the RIPC group compared with the sham control
group, this difference was not significant and the study was not powered to detect this individual
end point.
TABLE 11 Number and percentage of participants experiencing adverse events during follow-up
Adverse event Sham control (n= 811) RIPC (n= 801)
Any adverse event 354 (43.6) 364 (45.4)
Adverse event at time of RIPC/sham intervention 3 (0.4) 37 (4.6)
Unexpected adverse event 1 (0.1) 2 (0.2)
Skin petechiae 2 (0.2) 35 (4.4)
Adverse event during follow-up 353 (43.5) 349 (43.6)
Death 55 (6.8) 71 (8.9)
Hospital admission 267 (32.9) 257 (32.1)
Other reported adverse event 88 (10.9) 80 (10.0)
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Chapter 4 Discussion
In higher-risk patients undergoing CABG (with or without valve) surgery with blood cardioplegia,RIPC with transient arm ischaemia–reperfusion did not reduce MACCE (cardiovascular death, MI,
revascularisation and stroke) at 12 months following surgery compared with a sham control procedure.
Furthermore, RIPC had no effect on any of the major secondary end points.
Perioperative myocardial injury
Following cardiac surgery, the release of cardiac enzymes, including CKMB,23 troponin T24–26 and troponin
I,27–29 has been associated with worse short- and long-term clinical outcomes with a subsequent impact
on patient morbidity and mortality. One of the potential mechanisms underlying PMI during cardiac
surgery is represented by acute ischaemia–reperfusion injury secondary to intermittent aortic cross-clamp,
intermittent cross-clamp fibrillation or intermittent or continuous administration of cardioplegia.46 In this
regard, RIPC, describing the protection provided to an organ/tissue by a stimulus generated in a remote or
distant organ/tissue subjected to transient ischaemia–reperfusion prior to prolonged ischaemia, offers a
non-invasive strategy capable of reducing PMI in patients undergoing cardiac surgery and therefore
potentially improving their morbidity and mortality.
Remote ischaemic preconditioning
The concept of RIPC was first introduced by Przyklenk et al.,5 who found a significant reduction in MI size
in dogs subjected to four 5-minute cycles of circumflex occlusion prior to 1 hour of sustained left anterior
descending artery ischaemia. From this ‘intramyocardial’ application of ischaemic preconditioning (IPC),
Birnbaum et al.7 went on to demonstrate that ‘remote’ transient ischaemia in the hindlimb, applied with a
partial occlusion of the femoral artery in conjunction with rapid pacing of the gastrocnemius muscle, could
reduce MI size in rabbits. Subsequently, Kharbanda et al.9 were the first to apply the concept of RIPC to
healthy human volunteers by inducing transient non-invasive limb ischaemia with a simple blood pressure
cuff applied to one arm and demonstrating improved endothelial function in the contralateral arm.
Numerous small randomised controlled trials (RCTs) have followed this pioneering discovery with often
discordant outcomes: Cheung et al.12 were the first to apply RIPC in a clinical setting, randomising
37 children undergoing elective corrective surgery for a congenital heart defect to either a control
treatment or RIPC (four cycles of lower-limb ischaemia–reperfusion with a simple blood pressure cuff) and
demonstrating decreased PMI, inotropic requirements and airway resistance in the preconditioned group.
Similarly, Zhou et al.47 showed that, in children undergoing surgical repair of a simple ventricular septal
defect, RIPC (three 5-minute cycles of left upper-arm ischaemia–reperfusion 24 hours and 1 hour prior to
surgery) attenuated the systemic inflammatory response as well as myocardial and pulmonary injury.
Additionally, Pavione et al.48 failed to demonstrate enhanced cardioprotection or a reduced postoperative
inflammatory response with four 5-minute cycles of lower-limb ischaemia–reperfusion applied 24 hours
prior to corrective paediatric surgery.
However, it was in the setting of adult CABG surgery that understandably RIPC found an
extensive application.
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Remote ischaemic preconditioning in coronary artery bypass graft surgery
Our research group was the first to demonstrate that RIPC had the potential to reduce PMI in adult
patients undergoing elective CABG surgery.13 In a pioneering single-blinded RCT13 involving 57 patients
undergoing elective CABG surgery with either cardioplegia or intermittent cross clamp fibrillation and
randomised to RIPC (three 5-minute cycles of inflation and deflation of a blood pressure cuff placed
on the upper arm) or a control treatment (an uninflated blood pressure cuff placed on the upper arm
for 30 minutes) we found that preconditioned subjects had a 43% reduction in troponin T release over
the 72-hour perioperative period compared with control subjects. These findings were confirmed in a
further study involving 45 non-diabetic patients undergoing elective CABG with or without valve
surgery and receiving cold-blood cardioplegia alone,14 with RIPC (three 5-minute cycles of upper-arm
ischaemia–reperfusion) significantly reducing the 72-hour AUC of troponin T by 42.4%. The same
preconditioning stimulus was applied by Ali et al.49 in a study including 100 patients undergoing elective
CABG for two- or three-vessel CAD and similarly led to a significant reduction in postoperative
CKMB levels.
The concept of RIPC in the context of elective CABG surgery was then extended to patients receiving
antegrade cold crystalloid cardioplegia in two seminal studies by Thielmann et al.50,51 In one of the studies50
non-diabetic patients with triple-vessel CAD subjected to three cycles of 5-minute transient upper-arm
ischaemia sustained a significantly lessened PMI than control subjects, with a 44.5% reduction in the total
72-hour AUC of cardiac troponin I. In the other study,51 the largest proof-of-concept RCT on RIPC in
cardiac surgery so far, the same preconditioning stimulus improved myocardial protection (ratio of RIPC to
control for cardiac troponin I AUC was 0.83) and reduced the combined end point of all-cause mortality,
major adverse cardiac and cerebrovascular events and repeat revascularisation.
However, recently, a number of studies have failed to demonstrate significant RIPC-induced
cardioprotection. Within the context of crystalloid cardioplegia, Wagner et al.52 showed only a small
beneficial effect of RIPC applied 18 hours prior to elective CABG surgery with or without aortic valve
replacement. Similarly, Lomivorotov et al.53 did not find any statistically significant benefit of RIPC for PMI
in patients undergoing CABG surgery with cold crystalloid cardioplegia. In a trial involving 162 patients
undergoing CABG surgery, Rahman et al.54 found no statistically significant difference in troponin T release,
ECG changes, cardiac index, inotrope and vasoconstrictor requirements, renal impairment and lung injury
between patients receiving a sham protocol and patients receiving a RIPC protocol (three 5-minute cycles
of upper-limb ischaemia–reperfusion). However, importantly, the study included patients undergoing
elective or urgent (post-acute coronary syndrome) CABG surgery and it is therefore possible that the
beneficial effects of RIPC might have been attenuated by the previous acute event, which could have
already ‘preconditioned’ the patients. Moreover, in this double-blinded study, patients were prepared and
draped to obscure the visibility of both the blood pressure cuff placed around the upper arm and the one
placed around a ‘dummy arm’ and, although the correct inflation was verified though the disappearance
of a pulsatile signal on a pulse oximeter, it is still possible that during the inflation and deflation phases
the cuff might have moved and the RIPC stimulus might not have been delivered correctly. Third, and
importantly, a significant proportion of these patients received glyceryl trinitrate (GTN) intraoperatively,
which might have interfered with the cardioprotection provided by RIPC. Subsequently, Young et al.55
failed to demonstrate that a standard preconditioning stimulus could improve PMI, AKI incidence or
inotrope requirement in a study enrolling 96 patients undergoing high-risk cardiac surgery, including
combined CABG and valve surgery, CABG surgery with a LVEF of < 50%, ‘redo-operation’, mitral valve
surgery and double or triple valve surgery.
Additionally, Karuppasamy et al.56 showed no beneficial effects of standard RIPC in patients undergoing
elective CABG surgery and receiving the volatile anaesthetic isoflurane before cardiopulmonary bypass
and the intravenous anaesthetic propofol thereafter until the completion of surgery. Two other major
clinical studies used a strict anaesthetic regime with similarly no significant impact of RIPC on PMI.57,58
Furthermore, in a proof-of-concept study involving off-pump CABG surgery,59 RIPC induced by four cycles of
5-minute upper-limb ischaemia–reperfusion reduced the total cardiac troponin I AUC by 26%, which did
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not reach statistical significance. However, the same group found that the combination of RIPC with remote
ischaemic postconditioning (RIPostC) in an analogous surgical setting [the same stimulus was applied twice,
immediately after anaesthesia induction (RIPC) and just after completion of anastomoses (RIPostC)] could
lead to a significant cardiac troponin I AUC reduction in the preconditioned group.60 Crucially, our research
group has more recently been able to demonstrate that an enhanced preconditioning stimulus, consisting of
simultaneous multilimb RIPC, was able to reduce PMI and improve short-term clinical outcomes in patients
undergoing elective cardiac surgery. Additionally, a number of systematic reviews investigating the effects of
RIPC on PMI with or without clinical outcomes in patients undergoing cardiac or vascular surgery or elective
PCI have been conducted,61,62 concluding that RIPC reduces post-procedure myocardial damage in these
subjects but does not impact on their clinical outcomes.
It is also crucial to note that a significant part of the studies investigating the effects of RIPC on clinical
outcomes in patients undergoing elective cardiac surgery included surrogate end points such as
biochemical assessments of PMI through serial evaluation of serum levels of cardiac enzymes, yet very few
data are available in the literature with regard to the potential beneficial effects of RIPC on clinical
outcomes. The very first study to describe the impact of RIPC on patient morbidity and mortality in the
context of cardiac surgery reported no postoperative deaths in either the preconditioned group or the
control group 30 days after elective aortic valve replacement, mitral valve surgery or double valve
replacement.63 Similarly, no significant difference in MACCE was found 30 days postoperatively in two
small studies involving patients undergoing elective CABG surgery with crystalloid cardioplegia.50,53
Interestingly, in a study including high-risk patients,55 again no difference in mortality rate was found at
30 days post surgery; however, an improvement in NYHA functional status and mean LVEF at 3 months
postoperatively was found in preconditioned patients undergoing elective valve replacement.64
Additionally, in patients undergoing CABG surgery under a strict anaesthetic regime,58 RIPC was associated
with a higher perioperative composite end point of new arrhythmias and new MI, yet no significant
difference was found at 6 months’ follow-up.
Crucially, in the largest proof-of-concept clinical trial to date investigating the effects of RIPC in the context
of elective CABG surgery, unpublished at the time of the initiation of the ERICCA trial, Thielmann et al.65
reported a statistically significant improvement in all-cause mortality and MACCE rate in preconditioned
patients at 1 year and at completion of follow-up (1.54 years± 1.22 years), which was mainly driven by the
reduced incidence of new MIs, whereas no significant difference was found in the occurrence of cardiac
death, stroke and repeat revascularisation. Interestingly, of the 329 patients randomised and included in
the ITT analysis, 71 were excluded in the final PP analysis, of whom 61 had known diabetes and,
therefore, a total of 258 subjects were included in the PP analysis. However, the study was a single-centre
trial and adequately powered for the primary end point of PMI but not for secondary end points, including
clinical outcomes, and, crucially, despite still lower, the rate of all-cause mortality became non-statistically
significant when deaths from sepsis were excluded. In our single-centre RCT, we could not demonstrate
that simultaneous multilimb preconditioning reduces the rate of death, MI, revascularisation and stroke at
6 weeks post cardiac surgery, a finding that was also confirmed in the subsequent subgroup analyses;
however, once again the study was not powered for this type of evaluation.66 In addition, a significant
number of systematic reviews and meta-analyses in patients undergoing cardiac or vascular surgery or
elective PCI have been conducted;61,62,67–76 the overall conclusions confirmed the beneficial effects of RIPC
on PMI reduction, but no statistically significant improvements in clinical outcomes were observed,
including rate of death, perioperative MI, renal failure, stroke, mesenteric ischaemia or hospital or ITU stay.
Two recently published and adequately powered clinical trials in cardiac surgery failed to demonstrate any
beneficial effect of RIPC on inpatient clinical outcomes in 299 paediatric patients (primary end point of
postoperative hospital stay)77 and 1280 adult patients (combined primary end point of death, MI, arrhythmia,
stroke, coma, renal failure, respiratory failure, cardiogenic shock, gastrointestinal complication and multiorgan
failure),78 although the latter study used a combined remote pre- and post-conditioning stimulus.
DOI: 10.3310/eme03040 EFFICACY AND MECHANISM EVALUATION 2016 VOL. 3 NO. 4
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hausenloy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
35
In our ERICCA trial we demonstrated that four 5-minute cycles of upper-arm ischaemia–reperfusion were
unable to improve clinical outcomes at 1 year in higher-risk patients undergoing elective CABG with or
without valve surgery using blood cardioplegia. Multiple potential factors can be identified in this regard,
which can be divided into patient characteristics, clinical settings, anaesthetic regimes and other agents
administered in the perioperative period.
Patient characteristics involve baseline factors such as age and presence of comorbidities. More recently, the
risk profile of patients undergoing cardiac surgery has substantially changed because of the ageing
population.79 The response of ageing myocardium to cardioprotection provided by IPC, RIPC and RIPostC,
as well as by pharmacological agents including opioids, remains controversial.80 Moreover, it has been
established that the presence of comorbidities such as diabetes, hypertension and dyslipidaemia may interfere
with cardioprotection. Experimental studies have shown that the diabetic myocardium may have an increased
resistance to ischaemia–reperfusion injury compared with the non-diabetic heart, although significant
differences in results have been obtained from different animal models and with different techniques of
diabetes induction (reviewed by Galagudza et al.81). Intriguingly, cardioprotection provided by IPC may be lost
in ageing hypertensive hearts and discordant results have been obtained from experimental and human
studies evaluating the effects of dyslipidaemia on myocardial ischaemia–reperfusion injury and more
importantly on its impact on IPC, RIPC and RIPostC.82
In addition, pharmacological agents administered concomitantly with cardiac surgery may have a
significant impact on cardioprotection achieved with RIPC, in particular anaesthetic drugs and intravenous
nitrates. GTN, a nitric oxide donor widely used in the context of cardiac surgery to achieve rapid blood
pressure control and coronary vasodilatation,83 has been demonstrated to interfere with IPC and RIPC in
experimental studies; however, its role in the clinical setting is yet to be clarified.84–95 Inhaled anaesthetics
have been shown to provide myocardial protection in patients undergoing cardiac surgery,58,96–98 either
used alone or in combination with propofol.58,59 However, the use of propofol alone does not lead to
cardioprotection57 and this is probably because of the lack of action on adenosine triphosphate (ATP)-
sensitive potassium channels and its interference with reactive oxygen species, which have both been
implicated in mechanisms underlying RIPC.57 It is therefore possible that inhaled anaesthetics, either
alone or in combination with propofol, are capable of reaching the necessary threshold to induce
cardioprotection and that the addition of RIPC may not provide any further benefit. In our trial, > 90% of
patients received propofol at some point during surgery.
The clinical setting is another crucial aspect potentially able to interfere with cardioprotection. Patients
undergoing elective CABG surgery sustain an overall small magnitude of PMI compared with that observed
in patients presenting with STEMI.99 Moreover, preclinical investigations of RIPC have been largely confined
to experimental models of acute coronary artery occlusion/reflow (which represent the in vitro model of
STEMI), rather than more clinically relevant animal models of cardiopulmonary bypass surgery, highlighting
the discordancy between experimental and clinical cardioprotection studies.57,80,100
Crucially, given the recent developments of treatment options in CAD and, more importantly, the advances
in operative methods of myocardial preservation, surgical techniques and anaesthetic agents, it is possible
that the additional benefit provided to these patients by RIPC might not be significant or identifiable with
the current strategies.
It is also important to note that in our trial there was a suggestion of an increased risk of cardiovascular
death with RIPC. However, our study was not powered to detect a difference in this individual end point
and this finding should therefore be interpreted with caution. Crucially, the overwhelming majority of
previously published studies51,77 and meta-analyses75,101,102 have failed to demonstrate any harmful effects
of RIPC during cardiac bypass surgery in terms of mortality and, in fact, one recent study showed a lower
all-cause mortality rate with RIPC.51
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Our multicentre study had several potential limitations.
1. We did not standardise pre-/perioperative anaesthesia and medication, although this was because we
wanted to reflect current clinical practice in cardiac bypass surgery as much as possible.
2. The number of missing and incomplete data for some of the secondary end points.
3. Although an echocardiography substudy had been planned, because of logistical issues very few
patients were included in the study and so no meaningful data on left ventricular function were
available for analysis.
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Chapter 5 Conclusions
We conducted a multicentre, double-blind, randomised sham controlled trial in higher-risk adultpatients undergoing on-pump CABG with or without valve surgery with blood cardioplegia. RIPC,
consisting of four 5-minute cycles of ischaemia–reperfusion of the upper arm, did not provide evidence
of any beneficial effects on the combined primary end point of cardiovascular death, MI, coronary
revascularisation and stroke at 12 months. We also found no difference in any of the secondary end points
or in any subgroup analyses.
However, RIPC may still be beneficial in other settings of acute myocardial ischaemia–reperfusion injury
such as in STEMI patients treated with primary PCI, in whom the magnitude of myocardial injury is
substantially greater than for cardiac surgery. The CONDI2 (Effect of RIC on Clinical Outcomes in STEMI
Patients Undergoing pPCI)/ERIC-PPCI (Effect of Remote Ischaemic Conditioning on Clinical Outcomes in
STEMI Patients Undergoing PPCI) trial will investigate the effect of RIPC on major clinical outcomes in this
patient group. Furthermore, RIPC may have a role to play in organ transplantation, another setting of
acute ischaemia–reperfusion injury – the recently completed REPAIR (REmote preconditioning for
Protection Against Ischaemia–Reperfusion in renal transplantation) trial found that RIPC using transient arm
ischaemia–reperfusion preserved renal graft function at 12 months following renal transplantation.
It is therefore important that studies continue to investigate the potential mechanisms underlying RIPC, as
this may facilitate the translation of this simple, non-invasive, low-cost intervention into patient benefit.
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Manchester Royal Infirmary (63 patients, recruitment started 7 December 2011): Daniel Keenan (PI),
Gillian Cummings-Fosong, Lesley Doyle, Suzanne Elwood, Sarah Evans, Heather Iles-Smith,
Shylet Kanyama, Kirsty Maciver, Seamus McLoughlin, Niall O’Keeffe, Wendy Osborne, Karen Palmer,
Andreas Paschalis, Hannah Phillips (née Swift), Bradley Tallon and Sharon Williams.
Abertawe Bro Morgannwg University Health Board, Morriston Hospital, Swansea (25 patients, recruitment
started 6 February 2012): Aprim Youhana (PI), Natalie Blytt-Jordens, Alun Scott Davies, Claire Fagan,
Jane Griffiths, Christine Jones, Rosemarie Morgan, Jillian Scott and Rebeccah Thomas.
Cardiff and Vale University Health Board, Cardiff (seven patients, recruitment started 24 September 2012):
Dheeraj Mehta (PI), Delyth Braim, Sian James, Anish John, Ana Lopez Marco, Anna Luen, Sita Rania Rao Podila,
Rajani Rajnish, Jitendra Rathod, Tracey Roberts and Abby Waters.
Derriford Hospital, Plymouth (76 patients, recruitment started 23 November 2011): Jonathan
Unsworth-White (PI), Julie Alderton, Louise Barrett, Paula Brockman, Claire Brown, Wendy Colwell,
Clinton Lloyd, Sue Olver, Maxine Pearse, Nikki Persad, Tania Riches, Carolyn Stewart, Kate Tantam,
Darren Waugh and Rob Wosley.
Northern General Hospital, Sheffield (22 patients, recruitment started 31 July 2012): Norman Briffa (PI),
Michael Agyemang, Abiola Alli, Cheryl Bailey, Peter Braidley, Michelle Deighton, Joyce Fofie, Laura Hill,
John Humphreys, Yvonne Jackson, Alison Jenkins, Sharon Kerrison, Craig King, Jay Lindley,
Felicity Mackenzie, Gail Mills, Faith Okhuoya, Julie Sorrell, Rachel Walker, Rebecca Warren and
Alison Weedon.
Trent Cardiac Centre, Nottingham (44 patients, recruitment started 28 June 2012): David Richens (PI),
Rahul Basu, Karim Dakkak, Raj Jutley, Amr Mahmoud, Ganapathy Muthuswammy, Justin Richards,
Prashanth Sadhahalli, Matloob Shajar, Arvind Singh, Henry Skinner, Julian Skoyles, Adam Szafranek,
Gabor Ther and Louise Wyllie.
Blackpool Victoria Hospital (72 patients, recruitment started 31 December 2012): Amal Bose (PI),
Kirsty Angus, Emma Brennan, Melanie Caswell, Laura Flannery, Gemma Hatton, Lesley Helliwell, Lisa Lane,
Barbara Mitchell, Sherron Pickervance, Manij Puronit, Vivek Srivastava, Laura Ullyott, Vasanthi Vasudevan
and Charlotte Waterhouse.
Wythenshawe Hospital, Manchester (40 patients, recruitment started 3 May 2012): Nizar Yonan (PI),
Diane Daniel, Susan Ferguson, Emma Flook, Faisal Hashmi, Marie Kirwan, Deirdre Leonard,
Teresa Mcnamara, Amanda Moran, Anu Oommen and Heather Perks.
Glenfield Hospital, Leicester (17 patients, recruitment started 10 December 2012): Tom Spyt (PI),
Donna Alexander, Mark Hickey, Shiji Legi, Katrina Maxfield, Jacek Szostek, Martina Williams and
Sarah Worthy.
Southampton General Hospital (92 patients, recruitment started 14 September 2012): Sunil Ohri (PI),
Mark Apaya, Wendy Bannister, Gemma Beckett, Clare Bolger, Hannah Collins, Jasmin Crockett,
Andy Curry, Wei Deng, Paul Diprose, Emma Ekins, Ravi Gill, Kim Golder, Edward Grinyer, Angela Jarca,
Alexa King, Jessica Piper, Karen Salmon, Leanne Seaward, Natasha Tantony, Bryony Tyrell,
Beverley Wadams and Kirstin Wilkinson.
Leeds General Infirmary (65 patients, recruitment started 28 November 2012): David O’Regan (PI),
Zoe Beardow, Sian Birch, Stuart Elliot, Karen Griffiths and Elizabeth Wilby.
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James Cook University Hospital, Middlesbrough (41 patients, recruitment started 3 September 2012):
Andrew Goodwin (PI), Bev Atkinson, Ian Brown, Suzanne Cormack, Maggie Finlayson, Peter Hill,
Elaine Morley, Cath Richardson, Heather Robinson, Sue Simmons and Laura Thompson.
North Staffordshire University Hospital, Stoke-on-Trent (10 patients, recruitment started 28 May 2013):
Qamar Abid (PI), Loretta Barnett, Krys Castro-Foskett, Jane Delaney, Melanie Griffiths, Sue Gallagher,
Julie Machin, Michael Martin, Elizabeth Sellars and Jill Wain.
University Hospital Coventry (18 patients, recruitment started 19 December 2012): Sunil Bhudia (PI),
Emily Archer, Steven Clay, Stacey Gibbons-Smith, Catherine Gibson, Denise Gocher, Neil Hawthorne,
Jill Lindsay, Marie McCauley, Rosemary Musanhu, Pamela O’Meara, Jeff Ting and Geraldine Ward.
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Appendix 1
Summary of changes to the ERICCA protocol
Note on version numbers
Protocol version 5 (6 September 2010) was the first ethically approved version of the protocol and so is
considered the original protocol; versions 1–4 were drafts and have not been included in this document.
The following changes were made to version 6 (28 October 2010):
1. Further information has been added with regard to the definition of the primary objective, and the
study end point has been clarified as cardiovascular death.
2. Treatment period changed – the RIPC protocol has been changed from three 5-minute cycles to four
cycles of ischaemia and reperfusion applied to the upper arm. This is because of a recent publication19
which has shown that RIPC using four 5-minute cycles reduces infarct size in patients presenting with
an acute MI.
3. Changed from peripheral vascular disease to peripheral arterial disease, as the former is vague and
includes venous disease such as deep-vein thrombosis. Peripheral arterial disease is more accurate and
specific for the patients we would like to include.
4. The laboratory where we plan to undertake the troponin T assays for all of the sites has switched to
hsTnT, which has different cut-off values.
5. Further information included on calculating inotrope score.
6. Further details included with regard to ejection fraction protocol.
7. Clinical outcome confirmed as death and not cardiovascular death. Information will be collected on all
deaths. The definition of cardiovascular death was improved.
The following changes were made to version 7 (14 January 2011):
1. The laboratory where the samples are to be collected has been changed and, therefore, the size of the
tube in which blood is collected has changed.
The following changes were made to version 8 (1 March 2011):
1. Further centres have been added. It was originally felt that 11 centres would be adequate for
recruitment for this trial. However, following an investigator meeting it was decided to increase the
number of centres to ensure that the trial is recruiting on target and on time.
2. The total time for the intervention has been changed from 40 minutes to 35 minutes. This is because
the last 5 minutes is when the cuff is deflated and so it can be removed after the final inflation.
3. Recruiting centres will be advised to avoid the routine use of intravenous GTN during surgery, as this
agent may interfere with RIPC. The use of any GTN will be recorded on the patient’s CRF.
4. The following exclusion criterion has been removed: positive troponin T or I at baseline. This has been
removed as this status may not always be known as troponin is not measured routinely in these patients.
5. A definition of cardiogenic shock has been included as requested by investigators. This is a
standard definition.
6. The Doctors Laboratory will now analyse all troponin samples.
7. Information will be collected on the day of surgery on any angiograms that have been performed
during the last 5 days. During this procedure, dye is used and this may affect some of the blood tests.
8. As we have removed a positive troponin T or I at baseline as an exclusion criterion but are still
measuring troponin T and troponin I as part of the trial procedures pre and post surgery, they will be
reviewed further as part of the statistical analysis plan.
9. Richard Evans has now been added as the assistant trial manager.
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The following changes were made to version 9 (4 May 2011):
1. An earlier time point for assessment of MACCE was agreed to be of benefit. It has therefore been
added as a secondary end point at 6 weeks (which coincides with the first follow-up appointment of
the patients). In addition, all-cause death will be noted as a secondary end point.
2. The original plan was for the control group not to have the blood pressure cuff inflated. However, the
reviewers were concerned that this may unblind more staff. In light of this we have changed the
control group to a sham control group. When patients are randomised to the sham control group they
will undergo 5 minutes of simulated inflations of the blood pressure cuff followed by deflation.
3. As centres use different types of blood bottles, EDTA has been removed to avoid confusion at sites.
Blood samples can be stored at –20 °C and not –70 °C as originally thought.
4. Three-dimensional techniques have been added to measurement of the LVEF.
5. Samples for genetic analysis have now changed slightly following on from the advice of a biochemist.
6. Luciano Candilio has been added as a clinical fellow.
7. It has been decided that an independent EVC will be convened to adjudicate all of the events that
make up the primary end point.
8. The membership for the TSC has been updated.
9. Changes to inclusion criteria – recruitment to the trial has now started and all patients who are
undergoing CABG are screened. Many patients are not meeting the inclusion criteria and so we are
modifying these to maximise recruitment to the trial. There are two main changes: the euroSCORE is
being lowered from ≥ 6 to ≥ 5 and the word ‘cold’ has been removed from point 1.
10. Changes to exclusion criteria – bilirubin of > 20mmol/l has been deleted as this will also maximise our
recruitment and centres have been updated: Mr Aprim Youhana, Swansea Morriston Hospital, has
been added and Bristol Royal Infirmary has been removed.
11. In relation to the inotrope score some centres use milrinone and so this has been added.
The following changes were made to version 10 (12 January 2012):
1. The PI at Harefield Hospital has been changed from Professor John Pepper to Dr Andre Simon.
Nine other sites have been added to increase and accelerate recruitment.
2. The number of sites has increased from 16 to 28. The recruitment rates have been updated to reflect
the involvement of extra hospitals and the timetable has been updated to reflect the training of
28 sites.
3. St Thomas’ Hospital has now also agreed to take part in the echo substudy.
4. Cardiogenic shock and cardiac arrest are listed on separate lines on the CRF. Hepatic dysfunction has
been changed from using the prothrombin ratio definition to using the international normalised ratio
to reflect current practice.
5. The inotrope score has been adjusted slightly to incorporate alternative inotropes.
6. Dry ice is now being provided by the courier company and not locally to simplify transfer procedures.
7. The study timetable has been corrected to remove creatinine and urine volume at baseline as these
need to be recorded preoperatively only.
8. The reporting of events has been adjusted as many centres are submitting SAEs relating to
complications of CABG. Listed are the most common complications of surgery, which we hope will
lead to the reporting of fewer SAEs.
9. Wording changed in the consent procedure for inpatients recommending that they are given 24 hours
to consider the trial.
10. Trial unblinded statistician updated from Cono Ariti to Jennifer Nicholas.
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The following changes were made to version 11 (7 December 2012):
1. The number of recruiting sites has been increased from 28 to 30 to expedite recruitment.
2. The echo substudy has been opened to other sites to increase recruitment.
3. The wording for randomisation timing has been amended as some sites need to randomise earlier
than the morning before surgery for logistical reasons.
4. The recruitment targets have been amended to reflect expected recruitment numbers.
5. The requirement to record a screenshot of the euroSCORE has been removed to reflect the different
methods that sites use to calculate it. The screenshot of the euroSCORE calculator has been removed
from the appendix.
6. Wording has been changed to reflect the fact that the EQ-5D questionnaire can be completed over
the telephone.
7. Wording has been changed to reflect the fact that if a patient is unable to attend the 1-year follow-up
it may be conducted over the telephone.
8. Infection of donor site has been added to the list of expected SAEs.
9. The job descriptions of Richard Evans, Steven Robertson and Rosemary Knight have been updated to
reflect their current roles.
10. The details for the EVC have been added.
11. The primary end point definitions have been clarified after input from the EVC.
12. The list of local investigators has been finalised and updated.
The following changes were made to version 12 (27 November 2014):
1. Update to Derek Hausenloy’s title (Professor).
2. Update to remove troponin I from the list of blood samples as only hsTnT was collected for the trial.
3. Update to perioperative MI definition to match the current universal definition of MI. Updated to
include probable MI as a category to allow for cases in which sufficient evidence to consider definite MI
is not available.
4. Update to make clear that both definite and probable MIs will be included in the MACCE end point.
5. Update to stroke definition to allow probable stroke to be recorded when there is insufficient evidence
to classify as definite stroke.
6. Update to make clear that both definite and probable strokes will be included in the MACCE end point.
7. EVC updated to reflect membership changes.
8. Reference added supporting change to MI definition.
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